ILLINOIS POLLUTION CONTROL B02½RD
June 17, 1993
IN THE MATTER OF:
)
)
POTENTIALLY INFECTIOUS MEDICAL
)
WASTE (P1MW): TREATMENT, STORAGE,
)
R91-20
AND TRANSFER FACILITIES and
)
(Rulemaking)
TRANSPORTATION, PACKAGING, AND
LABELING (35 Ill. Adm. Code
)
1420, 1421, and 1422)
)
Adopted Rule.
Final Action.
OPINION AND ORDER OF THE BOARD (by R. C. Flemal):
This matter comes before the Board upon the mandates of the
Illinois General Assembly that the Board (1) adopt rules
regulating facilities for the treatment, storage, and transfer of
potentially infectious medical waste (P1MW) and (2) adopt
standards for the transportation, packaging, and labeling of
P1MW’. Today the Board adopts amendments to 35 Iii. Adm. Code
Part 1420 and new Parts 1421 and 1422 to meet these legislative
mandates.
The Board is charged under the Illinois Environmental
Protection Act (Act) to “determine, define and implement the
environmental control standards applicable in the State of
Illinois”2. The Board is thereby responsible for promulgating
the State’s substantive environmental regulations, such as
represented by today’s action. More generally, the Board’s
rulemaking authority is based on the system of checks and
balances integral to Illinois environmental governance: the Board
is charged with the rulemaking and principal adjudicatory
functions and the Illinois Environmental Protection Agency
(Agency) is charged with carrying out the principal
administrative functions.
Today’s regulations closely follow the recommendations of
the Governor’s Medical Waste Tracking Study Group (Study Group)
as that group’s consensus has been proposed to the Board by the
Agency. Today’s regulations also are identical to the
regulations adopted for second notice, with the exception of a
modification at subsection 1422
•
122 (a) (1) and several format and
nonsubstantive modifications made at the recommendation of the
Joint Committee on Administrative Rules (JCAR).
1 The mandates occur at Section
56.2
of the Illinois
Environmental Protection Act (Act), 415 ILCS 5/1 et seq.
2 Act at Section 5(b).
* n 7
t ‘)
Ut
nj
LJ~.UU
—2—
The Board wishes to acknowledge the special contributions
made to this proceeding by staff scientist LouAnn Burnett in her
roles as technical consultant and participant in regulatory
meetings with the Study Group, and to Board attorney Michelle C.
Dresdow in her roles as hearing officer, contact person, and
advisor in drafting of the several opinions and orders. The
Board also expresses its appreciation for the quality and
magnitude of the contributions made by the members of the Study
Group and other participants, and for the leadership provided by
the Agency.
HI STORY
Prior to discussing the particulars of the instant
regulations, it is instructive to place their development in
historical perspective. Although concern about infectious
materials is long standing, the impetus to today’s particular
action is more recent, with antecedents at both the federal and
state level.
National Concern with Medical Wastes
Broad public and national concern about medical waste
reached a heightened consciousness after medically—related
material washed up on beaches on the east coast during the summer
of 1987 and again on the east coast and on the Michigan shores of
Lake Michigan in the summer of 1988. In addition to general
health and aesthetic concerns, fear of AIDS contributed heavily
to the public’s anxiety regarding these wastes. (Exh. 7 at iii.)
Following the second season of wash—ups, Congress passed
Public Law 100-582, the Medical Waste Tracking Act of 1988
(MWTA). The NWTA has a research and information component that
has provided for an expanded understanding of the nature and
hazards associated with medical wastes3.
In addition, the MWTA requires that the United States
Environmental Protection Agency promulgate regulations to
establish a demonstration tracking system for medical waste.
Several states along the Atlantic Coast (Connecticut, New York,
New Jersey) were required to participate in the demonstration
program. Participation of states bordering the Great Lakes was
made optional.
~ Among the important MWTA documents is “The Public Health
Implications of Medical Waste: A Report to Congress”, prepared by
the Agency for Toxic Substances and Disease Registry (ATSDR) of
the Public Health Service, U.S. Department of Health and Human
Services. This document is Exhibit 7 in the instant record.
0 L~3-O26i.~
—3—
All of the Great Lakes States elected to opt out of the
federal MWTA demonstration program. Governor James R. Thompson
outlined several reasons for Illinois’ choice not to participate
(Exh. 5 at 8):
1. Illinois already had a system in place which
tracked the potentially infectious waste from
hospitals. It was estimated at that time that
approximately 60 percent of the potentially
infectious waste generated in Illinois came from
hospitals.
2. The intent of the MWTA was to prevent beach
closings, yet even USEPA concluded that the
program would have a very limited effect on the
beaches.
3. No funding would be available from USEPA to
implement the program in Illinois.
Medical Waste Trackinc~Study Group
Governor Thompson recognized, however, that there was need
for additional study and planning for Illinois’ medical waste
program. Accordingly, on December 28, 1989, he announced the
formation of the Medical Waste Tracking Study Group. The Study
Group consisted of elected officials4 and representatives of
state agencies5, the health community6, academia7, waste handling
groups8, agriculture9, and the City of Chicago’°.
~ State Senators Judy Baar Topinka, Margaret Smith, and
Virginia MacDonald, and State Representative Myron Kulas.
~ The Agency, the Board, and Illinois Department of Public
Health. Board Member Joan Anderson participated initially.
6 Including the Illinois State Medical Society (Dr. Larry A.
Von Behren), the veterinary community (Dr. Raymond 0. Hill),
Illinois Council on Long Term Care (Mr. Peter P. Peters), the
Illinois Hospital Association (Ms. Ann Guild), public health
departments (Mr. J. Maichle Bacon), the Association for
Practitioners in Infectious Control (Ms. Carol Mason), and the
Illinois Dental Society (Dr. Robert Colantino).
~ Dr. Van Allen Anderson, University of Illinois Urbana-
Champaign, and John Klaire, University of Chicago Hospital.
S Including Waste Management, Inc. (Ms. Janet S. Emmerman),
Sexton Environmental Services (Mr. Larry Lawrence), National
Environmental Services Corp. (Mr. Bill Smith), Browning-Ferris
Industries (Mr. Francis J. O’Brien), and Compliance Resources,
I I 2-
P91
J~3
—4—
The Study Group met on many occasions and reviewed a large
number of scientific, technical and legal materials preparatory
to issuing its findings. (Exh. 5 at cover letter.) The
culmination of these activities was the submission to Governor
Jim Edgar on June 10, 1991 of the Study Group’s report entitled
“The Regulation of Potentially Infectious Medical Waste in
Illinois”. The report contains background information on the
scope of the P1MW problem and recommendations for managing P1MW
in Illinois. These recommendations are directed to modifications
of law, as well as educational and voluntary actions. The
recommendations with respect to the law formed the basis for
subsequent legislative actions and for the regulations today
adopted.
Members of the Study Group have continued to participate in
P1MW legislative and regulatory developments, including
presentation of much of the proposal, testimony, and general
record upon which today’s action is based.
Legislative Action
During the spring 1991 legislative session, the Illinois
General Assembly in House Bill 2491 adopted a variety of
amendments to the Illinois Environmental Protection Act (Act) in
response to the Study Group’s recommendations. These were signed
into law on September 26, 1991 by Governor Edgar as Public Act
87-752, effective January 1, 1992.
One of the cornerstones of P.A. 87-752 is the definition for
potentially infectious medical waste’2 its greatest importance
is that it specifically limits the types of waste to which P1MW
regulations apply.
P.A. 87-752 also added to the Act new
Title XV: Potentially
Infectious Medical Waste.
This title consists of seven sections,
numbered Sections 56 through 56.6. Section 56 consists of the
findings of the General Assembly on the matter of P1MW and the
statement of purpose for Title XV. In its entirety Section 56
reads:
Inc. (Mr. Ed Juracek).
~ Mr. Richard P. Myers.
10 Ms. Nancy Marren.
~ This report is found in the instant record as Exhibit 5.
12 The definition was originally placed at Section 381 of
the Act. Pursuant to P.A. 87-1097 it was renumbered to Section
3.84.
‘3~
—5—
a. The General Assembly finds:
1. that potentially infectious medical waste, if
not handled properly, may constitute an
environmental or public health problem.
2. that potentially infectious medical waste, if
not handled properly, may present a health
risk to handlers of the waste at the facility
where the waste is generated, during
transportation of the waste, and at the
facility receiving the waste.
b. It is the purpose of this Title to reduce the
potential environmental and public health risks
associated with potentially infectious medical
waste by establishing statutory and regulatory
requirements to ensure that such waste will be
handled in a safe and responsible manner.
Section 56.1 is a lengthy’3 section consisting of a list of
prohibitions against P1MW activities. The principal prohibitions
are against:
1. Disposal of any P1MW (Section 56.1(a));
2. The landfill disposal of sharps unless their
infectious potential has been eliminated and
they are properly packaged (Section 56.1(a));
3. The delivery of P1MW for transport, storage,
treatment, or transfer except where the P1MW
is properly packaged (Section 56.1(b));
4. The delivery of P1MW to a person or facility
that does not have an Agency-issued permit
for storage, treatment, or transfer of P1MW,
where such permit is required (Section
56.1(c));
5. The delivery or transfer of P1MW unless the
transporter has an Agency—issued permit,
where such permit is required (Section
56.1(d));
‘~ A substantial portion of the length of Section 56.1 arises
from the inclusion of various effective dates (all now past
except for the incineration date found at Section 56.1(j)) plus
interim regulations which are to be in effect until the adoption
of the instant regulations.
I~
L I4O~J~O
—6—
6. The delivery or transfer of P1MW unless a
P1MW manifest is completed for the waste,
where such manifest is required (Section
56.1(d));
7. The acceptance of any P1MW for transport,
storage, treatment, or transfer except where
the P1MW is properly packaged (Section
56.1(e));
8. The conducting of any P1MW transportation
operation without an Agency-issued permit
(where such permit is required), in violation
of any permit condition, or in violation of a
Board regulation or order (Section 56.1(f));
9. The conducting of any P1MW treatment,
storage, or transfer operation without an
Agency-issued permit (where such permit is
required), in violation of any permit
condition, or in violation of a Board
regulation or order (Section 56.1(g));
10. The transport of unmanifested P1MW, where a
manifest is required (Section 56.1(h)); and
11. The incineration of P1MW after January 1,
1994 at an existing incinerator in violation
of standards established under Section 129 of
the Clean Air Act (Section 56.1(j)).
Section 56.2 consists principally of mandates to the Board,
including the mandates under which the instant action is being
undertaken’4. The first of these mandates is found at Section
56.2(a), and requires that the Board adopt regulations
“prescribing design and operating standards and criteria for all
potentially infectious waste treatment, storage, and transfer
facilities”. The mandate also directs that the Board, “at a
minimum” require that P1MW be treated at a facility that:
14 In addition to the mandates to which today’s action is
addressed, Section 56.2 also requires at subsection (d) that the
Board repeal its previous infectious waste regulations and at
subsection (e) that the Board adopt the list of Class 4 etiologic
agents. These two actions have been completed. The first was
undertaken as In the Matter of: Repeal of 35 Ill. Adin. Code
809.Subpart I: Hazardous (Infectious) Hospital Waste, R91—l8,
Final Order December 19, 1991. The second was undertaken as In
the Matter of: Potentially Infectious Medical Wastes: Etiologic
Agents, R9l—19, Final Order January 23, 1992.
0 L~3-O268
—7—
1. eliminates the infectious potential of the
waste;
2. prevents compaction and rupture of containers
during handling operations;
3. disposes of treatment residuals in accordance
with this Act and regulations adopted
thereunder;
4. provides for quality assurance programs;
5. provides for periodic testing using
biological testing, where appropriate, that
demonstrate proper treatment of the waste;
6. provides for assurances that clearly
demonstrate that potentially infectious
medical waste has been properly treated; and
7. is in compliance with all Federal and State
laws and regulations pertaining to
environmental protection.
The second mandate that today’s action addresses occurs at
Section 56.2(c). It specifies that the Board shall adopt
regulations “prescribing standards and criteria for transporting,
packaging, segregating, labeling, and marking potentially
infectious medical waste”.
Sections 56.3, 56.4, 56.5, and 56.6 of Title XV generally
deal with the Agency’s direct role in P1MW matters, including
reporting, manifesting,
permit
issuance, and fee collection.
Some of these matters bear peripherally on today’s action.
In the spring 1992 legislative session, the General Assembly
revisited P.A. 87—752 for the purpose of making certain
corrective amendments. These were proposed as House Bill 3666
and signed into law as P.A. 87-1097 on September 15, 1992. Among
pertinent provisions, P.A. 87-1097 clarified the definition of
P1MW, clarified various exceptions to the prohibitions of Section
56.1, and specified July 1, 1993 as the required date of
completion of the instant rulemaking.
Actions before the Board
In anticipation of the need to take action in the P1MW
arena, the Board on August 9, 1991 reserved several rulemaking
dockets within which it intended to conduct the various
rulemakings. On August 23, 1991 the Board called a public
hearing (inquiry hearing), which was held on September 18, 1991.
0
—8—
The purpose of this hearing was to determine the proper scope of
the regulations to be developed under the Section 56.2 mandates.
On August 26, 1991 the Board issued orders formally opening
the dockets. Included were separate dockets for the rulemaking
covering treatment, storage, and transfer facilities (R91—20) and
for the rulemaking covering transportation, packaging, and
labeling (R9l—21).
At the inquiry hearing testimony was received from Mr. Henry
Henderson from the City of Chicago, Dr. Van Allen Anderson of the
University of Illinois at Urbana-Champaign and the Study Group;
Ms. Ann Guild of the Illinois Hospital Association and the Study
Group; Dr. Larry Von Behren of the Illinois State Medical Society
and the Study Group; Mr. Joe Suchecki from Waste Management of
Illinois, Inc.; Mr. Francis 3. O’Brien from Browning Ferris
Industries Medical Waste Systems and the Study Group; Ms.
Jacquelyn Flora from Browning Ferris Industries Medical Waste
Systems; and Mr. Larry Lawrence of Sexton Environmental Systems
and the Study Group. Testimony and questioning included the
implementation provisions of the legislation requiring
segregation, packaging, marking and labeling, transporting,
storing and treating of P1MW (Tn.’5 at 98-144).
Based upon the inquiry hearing and in recognition that
matters of P1MW facilities and transportation, packaging, and
labeling overlapped, the Board on February 27, 1992 ordered
dockets R91-20 and R91-21 to be consolidated, docket R91-21 to be
closed, and the materials in docket R91-2l to be incorporated
into R9l-20 for the purpose of all subsequent considerations.
On April 27, 1992 the Agency filed the draft proposal upon
which the merit hearings have been held and upon which today’s
adopted rules are based; the Agency has also subsequently acted
as proponent for the instant rulemakings. Accordingly, for
purposes of the following discussions, the Board will identify
the April 27 draft proposal in short form as the “Agency
Proposal”. It is to be acknowledged, however, that the Study
Group and other interested persons contributed to the development
of the Agency Proposal, and moreover that the Agency undertook
extensive outreach and regulatory development meetings16 prior to
~ Citations to the pages of transcripts of the inquiry
hearing are in the form “Tn. at
____“;
citations to the
transcripts of the merit hearings, which are consecutively
numbered, are in the form “Tr2. at
16
Meetings were held on December 10 and 19, 1991, January 7,
23, and 24, 1992, and February 6, 7, and 24, 1992. Participants
included members of the Study Group in addition to other
interested persons. Ms. LouAnn Burnett and Mr. Philip Van Ness,
C, I
u1’~.u
L
—9—
formalizing and filing its proposal. The Board extends its
appreciation to the Agency and its personnel for the quality of
its leadership role.
On April 27, 1992 the Agency also filed a recommendation
(Exh. 37), pursuant to then Section 27 of the Act’7, that an
Economic Impact Study (EcIS) not be conducted; on May 11, 1992
the Illinois Department of Energy and Natural Resources joined in
that recommendation (PC
#7)18.
On June 4, 1992 the Board issued
an order finding that the EcIS need not be conducted. The Board
noted:
The Agency states that representative members of the
regulated community have participated in the
development of the Agency’s proposal, and that these
representatives will attend the hearings and present
information on the economic reasonableness of the rule.
The Agency has also presented some economic information
with its proposal (see Attachments 1—10), and will
present additional information at hearing. The
Department concurs in the Agency’s comments, and
further states that interested parties will have “ample
opportunity to present testimony regarding technical
feasibility and economic reasonableness during the
Board’s merit hearings.” (P.C.#7 at 1). The
Department further states that additional economic
information will be available from the Agency at or
before hearing.
Some of these representatives also participated on
the Medical Waste Tracking Study Group (Study
Group) formed by Governor Thompson. The Study
Group was instrumental in drafting the legislation
mandating the adoption of medical waste
regulations.
Board staff, also participated in these meetings. Minutes of
these meetings are included in this record as Exhibits 38-5, 38-
13, 38—35, 38—64, 38—65, and 38—66.
~ PA 87—860, effective July 1, 1992, deleted those portions
of the Act that required economic impact studies for this type of
rulemaking. The Board’s EcIS determination aside, the need for a
formal EcIS study is accordingly now moot.
‘~
Public comments are cited to in this opinion in the form “PC
#xat
0 ft3-027 1
—10—
The Board has held three merit hearings. These were held on
June 16, 1992 in Bloomington, Illinois, and on July 14, 1992 and
August 25, 1992 in Chicago, Illinois.
The June 16, 1992 hearing was devoted to presentation of the
Agency Proposal and the taking of questions on the proposal.
Providing testimony on behalf of the Agency were three members of
the Permit Section of the Agency’s Bureau of Land: Mr. Douglas
Clay, Manager of the Disposal Alternatives Unit; Dr. Shirley
Baer, Co-coordinator of the P1MW waste program, Disposal
Alternatives Unit, and Mr. Theodore Dragovich, Permit Reviewer.
Among persons posing questions to the Agency were ABB Sanitec,
Inc., Sexton Environmental Systems (Sexton), Winfield
Environmental Corporation, the National Solid Waste Management
Association (NSWMA), Chemical Waste Management, Isolyser Company,
and the Board.
The July 14, 1992 hearing focused on testimony directed to
the merits of the Agency Proposal. Among those testifying were
Dr. Cecil Lue-Hing of the Metropolitan Water Reclamation District
of Greater Chicago; Dr. Van Allen Anderson of the University of
Illinois,
Urbana-Champaign and the Study Group; Dr. Edward Cohen
of University of Illinois, Chicago, on behalf of Sexton; Mr.
Travis Honeycutt of Isolyser Company; Mr. Robert Rechner of the
Illinois State Dental Society and the Study Group; Ms. Ann Guild
of the Illinois Hospital Association and the Study Group; Dr.
Larry Von Behren of the Illinois State Medical Society and the
Study Group. Drs. Anderson and Von Behren, Mr. Rechner, and Ms.
Guild each spoke to the general support they and their
organizations give to the Agency Proposal, with Dr. Anderson
providing additional documentation in support of the position.
The other presenters generally spoke to specific concerns.
The August 25, 1992 hearing continued the opportunity for
testimony regarding the Agency Proposal and response testimony to
that given at the July 14 hearing. Witnesses included Ms. Jean
Furlan of the National Solid Waste Management Association; Mr.
Connie Frank of Rose Cartage; Mr. Harry Eiler of Recovery
Corporation of Illinois; Ms. Carol Mason of the Association for
Practitioners in Infection Control and the Study Group; Dr. John
Keene from the Society for Hospital Epidemiology of America; Mr.
Joseph Wilson of Ecomed; and Mr. Larry Eastep of the Agency and
the Study Group. Dr. Cohen also testified again. Ms. Mason
noted the support of her association for the Agency Proposal.
The other presenters generally spoke to specific concerns.
Public Comments
Thirty-nine public comments have been filed with the Board,
including nineteen filed subsequent to the start of merit
hearings and fourteen filed in the post—first notice comment
period.
These are dominantly expansions upon or responses to
0 ~3-8272
—11—
matters addressed at hearing or raised in the first notice
opinion. The Board has reviewed all public comments, with
citations herein where pertinent.
The Board notes that it recently received comment from Medx
Inc. and Custom Compactors Corporation. These comments were
received on May 10, 1993 and May 13, 1993, respectively, three
months after the February 11, 1993 close of the public comment
period and well after the Board adopted today’s rules for second
notice (see below). The Board is not able to react to such late—
filed comments; the Board is statutorily prohibited from altering
any proposal subsequent to second notice, except at the
recommendation of JCAR (see below).
First and Second Notices
Based on the record as then developed, the Board on December
3, 1992 adopted the first notice proposal’9. The proposed rules
were accompanied by a 39-page opinion, the major elements of
which are repeated in the instant opinion. In its outlines and
particulars, the first notice proposal closely tracked the Agency
Proposal.
On March 25, 1993 the Board adopted the second notice
proposal. The changes adopted for second notice were few and
generally were of the nature of giving greater specificity to the
regulations. The second notice proposal was accompanied by an
opinion of 28 pages, the major elements of which are incorporated
into today’s opinion.
Among changes made at second notice was adoption of a
recommendation of the National Solid Waste Management Association
that the operational definition of “eliminates the infectious
potential of the waste” found at Section 1422.122 (a) (1) be
clarified (PC #36 at 3). The intent was to provide a definition
that “more clearly reflects the treatment standards and more
clearly articulates the specific standards that constitute
elimination of infectious potential”. (Second Notice Opinion at
17.) The NSWMA comment, plus a similar comment from Stericycle
(PC #35), were filed prior to the end of the public comment
period, and prior to the time the Agency filed its comment. The
Agency, however, did not address this issue until after today’s
rules had gone to JCAR.
‘~
Publication of Part 1420 occurred at 16 Ill. Reg. 19625
(Dec. 18, 1992), Part 1421 at 16 Ill. Reg. 19615 (Dec. 18, 1992),
and Part 1422 at 16 Ill. Reg. 20002 (December 28, 1992).
I I ~
U~IJ
—12—
Action Before JCAR
Immediately upon adoption of the second notice rules, the
Board on March 26, 1993 forwarded them to JCAR pursuant to the
Illinois Administrative Procedure Act (5 ILCS 100/1-1 et seq.);
JCAR set the matter for consideration at its May 11, 1993
meeting.
On May 10, 1993 the Agency asked JCAR to object to adoption
of these rules on the basis that the modification made to Section
1422.122(a) (1)
--
see above
--
at second notice resulted in an
internal inconsistency between that subsection and some other
portions of Part l422~0. On May 11 JCAR voted the objection.
Under the terms of an objection, the Board is required to address
the objection.
This objection presented a number of concerns for the Board.
The first was that the objection delayed the adoption of the
entire set of rules pending resolution of the objection.
Moreover, it is statutorily required that this rulemaking process
be completed by July 1, 1993, further necessitating that action
be expeditious.
A second whole area of concern for the Board is that the
Board is statutorily and by its own rules and established
practices bound to the principle of equitable and impartial
hearing of the concerns of all interested parties on the public
record. Accordingly, if any person, the Agency included, wishes
the Board to modify the Board’s rules, it has available to it
clearly established public procedures by which petition may be
made.
Given the circumstances of the objection, the Board at its
first opportunity on Nay 20, 1993 ordered a special and short
public comment period to address solely the matter of the
appropriate language for subsection 1422.122(a) (1). To expedite
the matter, the Board suggested language that it believed would
address the JCAR concern. Further, the Board both invited
comment on the new proposed language and invited acceptable
alternatives; only the Agency responded.
On June 3, 1993 the Board voted adoption of the language
today found at subsection 1422.122 (a) (1) (see discussion below
for specifics), and submitted that language to JCAR via a Board
resolution as the Board’s response to the JCAR objection.
20
The Agency’s letter to JCAR requesting that an objection
be voted has not been served upon the Board; the Board
nevertheless takes official notice of it as a public document.
At no time, in fact, has the Agency addressed any of its
perceived problems with subsection 1422.122(a) (1) on the record.
Ci
~j
4~)U~.IL~
—13—
GENERAL CONSIDERATIONS
In addition to the history of P1MW matters, there are a
number of general considerations necessary to put today’s
regulations into perspective.
Immediacy of the P1MW Problem
While it is generally conceded that P1MW presents a real
problem, it is also generally conceded that the problem should be
addressed by a reasoned consideration of existing rules and
regulations and awareness of the professional practices employed
in those fields where P1MW is generated and handled. It was in
recognition of this situation that Illinois opted out of the MWTA
program (see above). It was also in recognition of this
situation that the broad interests represented in the Study Group
were brought together to recommend a concerted P1MW program.
It is also worth noting that the ATSDR’s report to Congress
(Exh. 7), made in accordance with the MWTA (see above), observed
that the general public’s health is not likely to be adversely
affected by medical waste generated in the traditional health
care setting and that OSHA’s “Occupational Exposure to Bloodborne
Pathogens” rule should decrease workplace medical waste—related
injuries and infections nationwide. (Exh. 7 at E.9.) ATSDR also
concluded that medical waste can be effectively treated by
chemical, physical, or biological means and that research
indicates that medical waste does not contain any greater
quantity or different types of microbiological agents than does
residential waste. Medical waste is approximately 0.3 of the
solid wastestream in the U.S. (Exh. 7 at E.11.)
Design of Rules
Today’s rules are designed as a multi—pronged attack on the
chain of events leading to infection and disease. For infection
to occur, each of these events must take place:
1) A person must come in contact with medical
waste;
2) An injury must occur following this contact,
thereby creating an appropriate portal of
entry, or a portal of entry must already
exist; and
3) A sufficient number of viable infectious
agents must enter a susceptible individual
via this portal of entry, then cause
infection.
0 1
r~.
* 02 /5
—14—
Infection does not always result in disease. (Exhs. 7 at E.5,
38—26, and 39—30 at 3.)
Appropriate segregation of P1MW from other wastes allows a
generator to apply more extensive safety measures to a smaller
waste stream. Proper packaging should nearly eliminate the
possibility of contact (Tr2. at 84) or the creation of a portal
of entry (i.e., packaging sharps in a puncture—proof container).
Storage and transportation requirements also help limit the
exposure of handlers or the general public to potentially
infectious agents. Treatment reduces the number of potentially
infectious agents, thereby reducing the possibility of infection
if contact and injury does occur. Any of these preventive
methods applied individually should reduce the possibility of
infection, but used in concert and properly, the entire P1MW
management system should reduce the possibility of infection
almost completely. (Tr2. at 113.)
Today’s rules are also designed to complement the
Occupational Safety and Health Administration rules issued
December 6, 1991 that contain provisions requiring employers to
protect their employees from bloodborne pathogens through
training, engineering controls, work practices, personal
protective equipment, recordkeeping, and Hepatitis Type-B virus
vaccinations (Exhibit 37-6; Tr2. at 72, 84).
Definition of Potentially Infectious Medical Waste (P1MW)
The definition of potentially infectious medical waste, or
P1MW, is set by statute at Section 3.84 of the Act. In its
entirety, that definition is as follows:
a. “Potentially infectious medical waste” or “P1MW” means
the following types of waste generated in connection
with the diagnosis, treatment (i.e., provision of
medical services), or immunization of human beings or
animals; research pertaining to the provision of
medical services; or the provision or testing of
biologicals:
1. Cultures and stocks. This waste shall include but
not be limited to cultures and stocks of agents
infectious to humans, and associated biologicals;
cultures from medical or pathological
laboratories; cultures and stocks of infectious
agents from research and industrial laboratories;
wastes from the production of biologicals;
discarded live or attenuated vaccines; or culture
dishes and devices used to transfer, inoculate, or
mix cultures.
r~~i
~
r~
U
—
U~
—15—
2. Human pathological wastes. This waste shall
include tissue, organs, and body parts (except
teeth and the contiguous structures of bone and
gum), body fluids that are removed during surgery,
autopsy, or other medical procedures; or specimens
of body fluids and their containers.
3. Human blood and blood products. This waste shall
include discarded human blood, blood components
(e.g., serum and plasma), or saturated material
containing free flowing blood or blood components.
4. Used sharps. This waste shall include but not be
limited to discarded sharps used in animal or
human patient care, medical research, or clinical
or pharmaceutical laboratories; hypodermic,
intravenous, or other medical needles; hypodermic
or intravenous syringes; pasteur pipettes; scalpel
blades; or blood vials. This waste shall also
include but not be limited to other types of
broken or unbroken glass (including slides and
cover slips) in contact with infectious agents.
5. Animal waste. Animal waste means discarded
materials, including carcasses, body parts, body
fluids, blood, or bedding originating from animals
inoculated during research, production of
biologicals, or pharmaceutical testing with agents
infectious to humans.
6. Isolation waste. This waste shall include
discarded materials contaminated with blood,
excretions, exudates, and secretions from humans
that are isolated to protect others frOm highly
communicable diseases. “Highly communicable
diseases” means those diseases identified by the
board in rules adopted under subsection (e) of
section 56.2 Of the act.
7. Unused sharps. This waste shall include but not
be limited to the following unused, discarded
sharps: hypodermic, intravenous, or other
needles; hypodermic or intravenous syringes; or
scalpel blades.
b. Potentially infectious medical waste does not include:
1. waste generated as general household waste;
2. waste (except for sharps) for which the infectious
potential has been eliminated by treatment; or
UI ~~3-0277
—16—
3. sharps that meet both of the following conditions:
A. the infectious potential has been eliminated
from the sharps by treatment; and
B. the sharps are rendered unrecognizable by
treatment.
Early in the history of this proceeding there was concern
raised by various persons about the appropriateness of this
definition. A portion of that concern was addressed by the
corrective amendments undertaken in P.A. 1097; these amendments
limited the types of waste that are P1MW21.
The remaining questions regarding the P1MW definition are
largely concerned with interpretation and implementation of
certain phrases used within the definition, as, for example, the
meaning of “rendered unrecognizable” found in the last subsection
of the definition. These will be discussed in context in the
following part—by—part analyses.
The Treatment Standard
The fundamental provision around which the instant
regulations are built is the provision of treatment to render
waste non—PIMW. Because a waste that is P1MW may not be disposed
of in Illinois, and because treatment is the process by which a
waste ceases to be P1MW22, the ultimate disposition of P1MW
depends upon its being treated.
Suitably, treatment standards and criteria form the largest
single portion, Subpart B of Part 1422, of today’s regulations.
Moreover, treatment has been the single greatest focus of
participant interest, both at hearing and in public comments.
Much of that interest has focused on the question of what
constitutes successful treatment.
21
The principal changes were to eliminate the phrase
“...
but not limited to
...“
prior to the lists of materials included
in the definitions of human pathological wastes, human blood and
blood products, and isolation waste, and to rephrase the
definition of animal waste.
~ A partial exception occurs for sharps. These must be both
treated and “rendered unrecognizable” in order to leave the P1MW
wastestream. “Recognizable” sharps, which remain P1MW, may be
disposed of provided that they are both treated and packaged,
pursuant to Section 1422.126. See discussion of the term
“recognizable” in the part—by-part discussion, below.
0 L~3-U278
—17—
Today’s regulations follow the Agency Proposal in requiring
two demonstrations of treatment efficacy. The first is the
Initial Efficacy Test~, in which it is required that the
manufacturer assure that six types of “test” microorganisms~
that are surrogates for pathogens be reduced to very low
concentrations (a 6—log reduction~) by the treatment process.
The second demonstration is made by operators of individual
treatment units. They are required to verify that the
manufacturer—demonstrated efficacy continues by conducting
Periodic Verification Tests26. These are accomplished by showing
that concentrations of bacterial spores (typically the most
resistant forms of microorganisms) are reduced to a number that
correlates with the 6—log reduction of the organisms used in the
manufacturer’s efficacy test.
This program represents the consensus view of members of the
Study Group, and the program which today is adopted in its major
provisions. Nevertheless, several issues regarding treatment
standards constituted major areas of debate during the course of
this proceeding.
Among such issues have been the stringency of the efficacy
standard, whether the standard is properly a “log—kill” or “log—
reduction” standard, and which organisms should be used or
allowed in efficacy determinations. Greater detail regarding
these issues has been presented in the first notice opinion at
pages 15-18 and 34-40 and the second notice opinion at pages 16-
26.
ORGANIZATIONAL CONSIDERATIONS
The Board has established the following organizational
scheme to accommodate the P1MW and related regulations.
~ See Section 1422.124.
~ Staphylococcus aureus
(representative of gram—positive
bacteria),
Pseudomonas aeruqinosa
(representative of gram—
negative bacteria),
Candida albicans
(representative of
vegetative fungi--yeast),
Trichophyton mentaqrophytes
(representative vegetative fungi--mold), MS—2 bacteriophage
(hepatitis virus surrogate, and
Mycobacterium smegmatis
(tuberculosis bacteria surrogate).
“
At various places in the record this term is also given as
“6log”. The hyphenated form is used here and in the text of the
regulations.
26
See Section 1422.125.
U
~43-027g
—18—
Subtitle M, which is to consist of the 1400—1499 series of
35 Ill. Adiu. Code, is reserved for regulations that control
specific biological materials; currently, the only Board
regulations within Subtitle M are the instant P1MW regulations.
As is the general scheme with 35 Ill. Adm. Code regulations,
parts numbered 1400 to 1449 (Chapter I) are reserved for
regulations promulgated by the Board, and parts numbered 1450 to
1499 (Chapters II and III) are reserved for regulations
promulgated by the Agency or the Department of Energy and Natural
Resources.
Today’s specific regulations are collected into subchapter
b, the P1MW subchapter. This subchapter, in turn, is subdivided
into three parts to efficiently house general provisions (Section
1420), and the regulations today adopted in response to the
separate Section 56.2(a) and 56.2(c) mandates of the Act
(Sections 1421 and 1422)
PART-BY-PART ANALYSIS
-
Part 1420
In this portion of our opinion, the Board presents an
explanatory analysis of today’s regulations, beginning with Part
1420. Emphasis is on issues that have required Board
resolution~.
Part 1420 is the only one of the three parts in today’s
regulatory package that is not entirely new. Part 1420
originated in the Board’s first P1MW proceeding, R91-19, that
dealt with etiologic agents28. It is expanded to house general
provisions pertaining to P1MW.
Scope and Ai~licability (Section 1420.101)
The Scope and Applicability statement for the P1MW
regulations was adopted in R91-19. At first notice the Board
proposed, and today adopts, the deletion of both subsection (b)
and the Board Note as no longer reflective of the overall content
of either Part 1420 or the P1MW subchapter.
It is to be noted that, through the operation of Section
1420.101, the instant regulations are applicable to activities
occurring in whole or in part within the State of Illinois.
Thus, that part of any P1MW wastestream activity (e,g.,
v The interested person is directed to the testimony of Dr.
Baer, Tr2. at 52—153, and Mr. Dragovich, Tr2. at 154—191, for a
more extensive explanation of particular provisions.
28 See footnote #14.
r
~I4$-~J~o0
—19—
transporting) that takes places in Illinois is subject to these
regulations, even if some portion of the P1MW wastestream
activity (e.g., disposal) does not.
Definitions (Section 1420.102)
General definitions that apply to the three P1MW parts are
found in Section 1420.102. Most of these definitions are
standard, and need not be specifically discussed here. However,
there are several around which question has been raised.
“P1MW”. The full statutory definition of P1MW has been
presented and discussed above. It is also presented within the
body of the rule at Section 1420.l02~. As noted above, there
have been some concerns raised regarding this definition that
have now been addressed by the General Assembly. The Board has
no authority to modify the statutory definition.
In response to a question raised by Chemical Waste
Management (CWN) regarding whether discarded unused test kits
should be considered P1MW (Tr2. at 282-305; PC #22), the Board in
its first notice opinion proposed that any waste containing blood
components was P1MW:
As a general rule, a waste is not a P1MW if it has no
infectious potential and is otherwise not explicitly
identified in the statutory definition of P1MW
.
It follows that an unused medical test kit, where the
test kit is not in whole or part a culture or stock, an
unused sharp, contains blood components, or somehow
otherwise covered under the statutory P1MW definition,
is not P1MW. (First notice opinion at p. 22, emphasis
added.)
During the post—first notice comment period, two commenters
observed that a discarded unused test kit that contains blood
components should not be considered to be P1MW. The Agency
observed that P1MW is by statutory definition waste generated
in
connection with: (1) the diagnosis, treatment or immunization of
human beings or animals; or (2) research pertaining to the
provision of medical services; or (3) provision or testing of
biologicals. (PC #39 at 2.) The Agency further observed that
unused test kits that contain blood components should not be
regulated as P1MW since they are not generated in connection with
any of these situations.
(u.)
Dr. Anderson also observed that
blood components in test kits have been sterilized, and as such
have no infectious potential. (PC #37 at 1.) In its second
~ It is to be noted that, in accord with standard
construction, statutory language in the regulations is denoted by
capitalization.
I I
‘~—
p1’)
1)1 4u L)~.
—20—
notice opinion, page 3, the Board noted that these points with
regard to unused test kits are well taken, and accordingly
receded from its first notice proposed position on this matter.
“Site”. The term “site” appears in many places within the
today’s regulations, including within other definitions (“storage
site” and “transfer station”), within provisions defining the
circumstances under which permits and manifests are required3°
and within various provisions defining on— and off—site
circumstances31. There is thus a special importance to having
the definition be clear and precise.
The following definition was offered in the Agency Proposal:
“SITE” MEANS ANY LOCATION, PLACE, TRACT OF LAND,
AND FACILITIES, INCLUDING BUT NOT LIMITED TO BUILDINGS,
AND IMPROVEMENTS USED FOR PURPOSES SUBJECT TO
REGULATION OR CONTROL BY THIS ACT OR REGULATIONS
THEREUNDER. (Section 3.43 of the Act). In the case of
a hospital or an educational institution, the Agency
shall determine what constitutes a site based on
location, ownership, operation, charter or license.
The first, capitalized part of this definition is identical
to the definition of “site” found in the Act. It has not been at
issue.
However, the second, lower case part of the definition has
been of concern. The purpose of the language is to allow for
flexibility in determining the geographic bounds of a site,
particularly in the circumstance where an organization
(epitomized by hospitals and universities) may consist of
geographically separated buildings and structures. The intent is
that such organizations need not necessarily acquire separate
permits for each structure or manifest all loads transferred
between buildings. The Agency’s resolution of this matter was to
allow a case—by—case determination under its supervision.
The problem with this resolution is that it constitutes a
delegation of authority of questionable validity. Accordingly,
the Board at first notice declined to propose the lower case
language of the Agency Proposal. Instead, at the lead of several
participants, the Board observed that the term “campus” has
sufficient ordinary meaning as to itself be explicit, and
~ Sections 1420.105(c) (1) and (e)(1).
31 Sections 1421.120, 1421.130, 1421.131(a) (2) (E),
1421.131(e)(2)(E), 1422.111(a), 1422.111(a)(4), and
1422.111(b) (5) (B).
• l.f s~_n9r~
0~) ~..O
—21—
therefore proposed to address the matter by replacing the lower
case language with:
For the purpose of this Subtitle, each campus of an
educational institution is considered to be a single
site.
This resolution did not explicitly address the issue of
hospitals. However, based on additional comments received in the
post-first notice comment period, the Board at second notice
concluded that it would be both unnecessary and unwise to attempt
more explicit consideration of hospitals within the definition of
“site”. This conclusion is based, among other matters, on the
special mention made of hospitals, and the permits required by
them, both in the statute and within the main body of the instant
regulations. (See second notice opinion at p. 4—7.) The Board
today affirms its analysis as presented at second notice.
Unrecognizable. Pursuant to the definition of P1MW at
Section 3.84 of the Act all sharps are considered to be P1MW
unless they meet both of the conditions:
The infectious potential has been eliminated from the
sharps by treatment; and
The sharps are rendered unrecognizable by treatment.
This definition has raised the question of how the phrase
“rendered unrecognizable” is to be interpreted32. The issue is
significant in that it factors into a determination of when a
sharp no longer is a P1MW, and hence is no longer subject to P1MW
treatment and disposal limitations33.
In the original Agency Proposal it is recommended that the
term “unrecognizable” be included within the general definitions,
as follows:
“Unrecognizable” means physical alteration (i.e.,
melted, charred, corroded, or ground) so that the sharp
may no longer be used for its intended purpose.
As the Board concluded at first notice, an effect of this
recommendation is to incorporate into the definition the concept
of usability. The Board also concluded that this incorporation
32 The meaning of infectious potential being “eliminated” has
also been raised in this proceeding. A discussion of this matter
is found in the “General Considerations” portion of this opinion,
above.
~ See discussion of Section 1420.104, below.
UI ~3-D283
—22—
is consistent with the P1MW threat posed by sharps and the
circumstance under which that threat is allayed. The Board
accordingly adopted the concept~. (See first notice opinion at
p. 25.) The Board today affirms these conclusions.
Also at first notice the Board discussed the encapsulation
and solidification process of Isolyser Company, Inc., as a method
for the treatment of sharps35. (First notice opinion at p. 25.)
For second notice Isolyser asked that “encapsulating/solidifying”
be specified in the definition of “unrecognizable” as an example
of physical alteration. (PC #30 at ¶1.) This the Board declined
to do because it believes that the record does not support a
blanket endorsement of all processes that involve encapsulation
or solidification. (Second notice opinion at p. 7.) The Board
today affirms these analyses.
Incorporations bY Reference (Section 1420.103)
Incorporations by reference for the full P1MW subchapter
occur at Section 1420.103. All incorporations are placed in one
section to simplify future amendments and updates, and for more
ready reference.
Today’s regulations contains two incorporations by
reference. They are Standard Methods for the Examination of
Water and Wastewater (18th Edition) and Test Methods for
Evaluating Solid Waste. Physical/Chemical Methods (EPA SW—846)~.
Prohibitions (Section 1420.104)
Section 1420.104 sets out the P1MW prohibitions. Much of
the section is statutory, as found at Section 56.1 of the Act.
Disposal of sharps. In a post-first notice public comment
Stericycle, Inc., requested clarification of sharps disposal, as
~ The actual language adopted was slightly modified for
grammatical reasons. See first notice opinion at p.26.
~ Under the Isolyser process sharps are treated and bound
into a polymer matrix. During the binding process pressure
forces the polymer into the barrels of syringes and needles, with
the whole enclosed in an opaque container. Isolyser contends
that this process renders the sharps no longer usable (Tr2. at
279; 663—94).
~ The former is referenced in the Initial Efficacy Test
procedures at Section 1422.124(e) (2) and 1422.Appendix A, and in
the Periodic Efficacy Test procedures at Section 1422.125(b) (4).
The latter is referenced in the Initial Efficacy Test procedures
at 1422.Appendix A.
r
L~ju28!4
—23—
referenced at Section 1420.104(a). (PC #35 at 2.) Stericycle
noted the absence of a requirement that sharps be rendered
“unrecognizable” before disposal in a landfill. In addressing
Stericycle’s concern, the Board notes that there are two portions
of the Illinois Environmental Protection Act and one section of
the regulations that reflect on the disposal of sharps. The
first is in the definition of P1MW37 at Section 3.81(b) of the
Act:
(b) Potentially infectious medical waste does not
include:
***
(3) sharps that meet both of the following
conditions:
(A) the infectious potential has been
eliminated from the sharps by treatment;
and
(B) the sharps are rendered unrecognizable
by treatment.
This definition thereby establishes that sharps that have had
their infectious potential eliminated and have been treated and
are rendered unrecognizable no longer meet the definition of
P1MW.
It is further established at Section 56.1(a) of the Act
that:
No person shall:
(a) cause or allow the disposal of any potentially
infectious medical waste. Sharps may be disposed
in any landfill permitted by the Agency under
Section 21 of this Act to accept municipal waste
for disposal, if both:
(1) the infectious potential has been
eliminated from the sharps by treatment;
and
(2) the sharps are packaged in accordance
with:
(A) Board regulations; or
~ The same definition is repeated at Section 1420.102 of the
instant regulations.
‘~
— U~
u5
—24—
(B) subsection (b) (2), until Board
regulations relating to the
packaging of potentially
infectious medical waste are
adopted and effective.
(emphasis added.)
The reference to sharps in this section is contained in an
exception to the prohibition of disposal of P1MW in landfills.
Pursuant to Section 3.81(b) (3), sharps that are unrecognizable
and treated are not P1MW at the time of disposal. Thus, Section
56.1 applies only to those sharps that remain P1MW after
treatment (i.e., sharps that have not been rendered
unrecognizable).
Read together, these two sections of the Act therefore
establish that there are two pathways by which sharps may
ultimately be disposed. The first is to package, treat, and
render the sharps unrecognizable. After this processing, the
sharps are not considered to be P1MW and may be disposed of in a
manner the same as that of any solid waste. However, if the
sharps are packaged and treated appropriately, but are not
rendered unrecognizable, those sharps may still be landfilled
under the exception provided in Section 56.1 of the Act.
This dual disposal pathway is reflected in the
recommendation of the Study Group, the Agency Proposal, and the
instant regulations at Section 1422.126:
Section 1422.126 Sharps
Sharps may be disposed in a landfill only if they have
been treated to eliminate the infectious potential and:
a) Have been rendered unrecognizable and therefore
are no longer P1MW; ~
b) Have been:
1) Packaged, marked, and labeled in accordance
with Part 1430, Subparts C and D;
2) Delivered by a transporter with a P1MW
hauling permit as required by Section
1420.104 of this Subtitle, unless
specifically exempted.
3) Accompanied by a P1MW manifest as required by
Section 1420.104 of this Subtitle, unless
specifically exempted.
t.
U
II
I
4~U286
‘~
—25—
(emphasis added)
The “or” in subsection 1422.126(a) indicates that either route is
an acceptable handling of sharps.
Distosal into sewers. Among the changes made to Section
1420.104 during the course of this proceeding has been the
addition at subsection (1) of an explicit prohibition against the
discharge of P1MW into sewers.
This action arose from concerns of the Metropolitan Water
Reclamation District of Greater Chicago (MWRDGC) and the Illinois
Association of Wastewater Agencies that the practice of flushing
ground/shredded inert medical solid wastes into sewers is an
inappropriate use of the public sewerage system, and that the
public sewerage system is neither designed to function as a
landfill nor as a depository for inert solid wastes regardless of
origin. (Tr2. at 468—493; Exh. 43 and 44; PC #6, 11, and 12.)
MWRDGC also observed difficulties posed to the biological
treatment system of a sewage treatment plant and sludges when
such solid materials are received in the waste stream. (Tr2. at
478—80.)
Permit and Manifest Exceptions. Penalty Factor, and Cleaning and
Disinfection (Sections 1420.105, 1420.106. and 1420.107)
The first two of these sections basically present language
from the P1MW statute. The third contains at a single location
language required in support of various other sections38.
The three sections have remained basically unaltered from
the Agency Proposal, although conforming and minor amendments
have been made, as discussed in the first notice opinion at page
28-29 and in the second notice opinion at page 11-12.
Severability (Section 1420.120)
Section 1420.120 contains severability language as found
generally in Board regulations.
PART-BY-PART ANALYSIS
-
Part 1421
Part 1421 is a new part intended to address the mandate of
Section 56.2(c) of the Act regarding the prescription of
“standards and criteria for transporting, packaging, segregating,
labeling, and marking potentially infectious medical waste”. The
38 Within the definition of “reusable container” at Section
1420.102, as well as at Sections 1421.121(d), 1421.121(e),
1421.141(i), 1422.111(a) (8), 1422.111(a) (11), and 1422.122(b) (5).
1
U~...L)
—26—
part is divided into five subparts, each addressing one of the
natural divisions of the topic. Part 1421 also has an Appendix A
that contains the International Biohazard Symbol.
The entire part is adopted today with only minor, generally
nonsubstantive modification from the Agency Proposal.
General Provisions (Subpart A)
This short subpart contains a single section specifying that
the date for compliance with Part 1421 is the effective date of
the part. That is, compliance is required immediately upon the
regulation becoming effective; that, in turn, will be upon the
acceptance by the Office of the Illinois Secretary of State of
the filing by the Board of today’s action.
Waste Segregation (Subpart B)
Subpart B consists of two sections that apply to all P1MW
generators, transporters, storage sites, transfer stations, and
treatment facilities (Section 1421.110).
A principal requirement, found in Section 1421.111(a), is
that generators segregate P1MW into sharps, oversized P1MW (a
single waste item that is too large to be placed into a 33-gallon
bag or container), and all other. These three categories are
derived from similar categories used in Section 56.1 of the Act,
including the interim P1MW regulations found there.
Subsections 1421.111(b) and (c) specify that properly
packaged and labeled sharps and mixed waste must be handled as
though the entire wastestream originated as P1MW. They do not,
however, preclude the applicability of other regulations. For
example, if a hazardous substance is also P1MW, both the
hazardous waste and P1MW rules are intended to apply.
This latter provision has raised the question of whether
rules that govern a waste as P1MW and rules that govern the same
waste under another categorization (e.g., hazardous waste) could
be incompatible. (Tr2. at 252-268.) The Board does not
immediately see that this presents a problem. As the Agency
indicates, a waste that is both P1MW and a hazardous waste may
occur, but is likely to be rare. (Tr2. at 271—276.) Where
overlap does occur, compliance with rules applicable to both P1MW
and hazardous wastes is required.
Packaging (Subpart C)
Subpart C consists of standards and criteria for packaging
that apply to any person who packages P1MW for off—site
transportation. (Section 1421.120.)
0
L~.3-O2B8
—27—
The standards and criteria, which are found in Section
1421.121, are designed to prevent discharge and protect handlers
from contact with P1MW (Tr2. at 27). They include packaging
requirements for all P1MW, with different standards for sharps
and oversized P1MW. Also included are standards for reusable
containers, standards for the management of the outside of
containers that are contaminated by P1MW, and standards for
residues from the cleaning of P1MW containers or discharges from
packages.
It is broadly believed that packaging is a critical element
in P1MW management, and that Subpart C correctly addresses that
matter. Subpart C is fashioned on the premise that performance
standards, rather than design standards, provide the most
effective method of assuring good P1MW management (Tn. at 100,
137; Exhs. 38—5, 38—13, 38—35, 38—64, 38—65, and 38—66).
Labeling and Marking (Subpart D)
This subpart applies to any person who packages P1MW for
off—site transportation or who accepts packages from off—site.
The specific standards for labeling and marking are found in
Section 1421.131. Among these are requirements for marking the
exterior of the outer package by the generator and
transporter(s), and different standards for marking sharps
containers and oversized P1MW.
Transportation (Subpart E)
This subpart applies to transporters required to have a P1MW
hauling permit. It contains requirements regarding the
conditions under which P1MW can be transported, including the
condition of the vehicle, the management of the packages, the
information that must be displayed on the vehicle, the emergency
response plan that is required to be kept, and a 10 calendar—day
limitation for the transportation of P1MW.
Dedicated vehicles. At hearing the issue was raised as to
whether it was necessary to require “dedicated vehicles” for P1MW
transportation39. (Tr2. 776-814; Exh. 54.) In particular, it
was asked whether “long—haul” vehicles (i.e., those vehicles that
engage in interstate transport) should be allowed to backhaul
“hardgoods” (paint, water seal stains, plastic, etc.) after the
~ Subsection (i) reads: “Vehicles transporting P1MW cannot
be used for the hauling of non—waste materials, with the
exception of equipment and supplies intended for the use of waste
management, new P1MW containers or P1MW containers that have been
cleaned and disinfected in accordance with 35 Ill. Adm. Code
1420.107 of this Subtitle”.
U I ~3-0289
—28—
vehicle has been decontaminated in accordance with the procedures
given in Section 1420.107. (Tr2. at 796, 805.)
At first notice the Board proposed to follow the
recommendation of the Study Group and the Agency by requiring
“dedicated vehicles”. At second notice the Board again addressed
the issue, and observed that post—first notice public comments
uniformly contended that no exceptions to the prohibition against
hauling non—PIMW loads should be allowed beyond those already
specified within 1421.141(i). (See second notice opinion at p.
14.)
Manifests. The Environmental Protection Act sets out
various requirements of P1MW handlers that are met through the
use of manifests. Most specifics regarding the form and use of
these manifests are either statutory or statutorily within the
purview of the Agency40. This notwithstanding, the Board at
first notice raised the issue of whether, for the sake of clarity
within the instant regulations, some additional presentation of
the use of manifests is needed. (First notice opinion at p. 32.)
None of the post—first notice public comments rose to this issue,
and accordingly no further consideration of manifests within the
bounds of today’s rules has been entertained by the Board.
PART-BY-PART ANALYSIS
-
Part 1422
Part 1422 is addressed to the mandate of Section 56.2(a) of
the Act regarding the prescription of “design and operating
standards and criteria for all potentially infectious waste
treatment, storage, and transfer facilities”. Like Part 1421,
Part 1422 is a new part.
Effective Date (Section 1422.101)
This section specifies that• the date for compliance with
Part 1422 is the effective date of the part. That is, compliance
is required immediately upon the regulation becoming effective41.
~° See, for example, the Act at Sections 56. 1(d) (2), 56.1(h),
and 56.4.
41 This provision notwithstanding, it should be noted that in
certain circumstances the requirements for an existing unit are
different than those for a unit that begins operation after the
effective date. An example is the Initial Efficacy Test
requirement for an autoclave, incinerator, or ethylene oxide unit
at Section 1422.123(c).
—29—
Permit Applications (Sections 1422.105 throu~h1422.107)
At first notice the Board raised an issue concerning the
need for greater specificity and clarification in the regulations
regarding the procedures for, and contents of, applications for
permits for treatment, storage, or transfer operations. (First
notice opinion at p. 18-19.) The Agency in response submitted
recommended provisions addressing application requirements. (PC
#39 at 5—12.)
The Board accordingly at second notice added three new
sections, Sections 1422.105, 1422.106, and 1422.107, that track
the Agency’s recommendation. The first section deals with
content of the application, the second with application
certifications, and the third with application filing
requirements. In each case, the provisions closely track similar
permit application provisions found in the Board’s landfill
regulations at 35 Ill. Adm. Code 812.
The addition of Sections 1422.105 through 1422.107 also
required collateral amendments at Section 1420.105(a) and (d).
Storage/Transfer Operations (Subpart B)
Subpart B consists of two sections that apply to the owner
or operator of any P1MW storage operation42. The subpart is
adopted today without substantive modification from the Agency
Proposal.
Design and operating requirements, which occur at Section
1422.111, constitute the principal standards and criteria of the
subpart. Standards and criteria applicable to any person who
stores P1MW prior to treatment or disposal on—site or transport
off—site are contained in subsection (a); these apply whether or
not a permit is required for the storage operation. Many of
these standards are repeated from Section 56.1(e) of the Act,
including requirements for maintaining the integrity of the
packages, limiting access to the storage operation, maintaining
the P1MW in a nonputrescent state, and protecting the P1MW from
animals and vectors. Other requirements in this subsection
include the management of reusable P1MW containers and residues,
retention of manifest copies, and closure of the storage
operation.
42 For the purpose of 1422.Subpart B a storage operation is
defined at Section 1422.110 to collectively include a “storage
site” or a “transfer station”. The latter two terms are defined
in the Act at Sections 3.47 and 3.83, respectively, and repeated
in the instant regulations in the definitions at Section
1420.102.
01 i~3-U29I
—30—
Subsection 1422.111(b) contains additional standards for
those storage operations that are required to have a permit.
These generally are facilities that receive waste from off—site.
(Tr2. at 30.) The standards include more detailed requirements
regarding to operating records, aisle space, the manner of
storage, signs, personnel training, contingency plan, storage
time limitations, and notification of closure. As the Agency
notes:
These requirements are necessary to meet the intent of
the Act to reduce the potential environmental and
public health risks associated with P1MW, since the
permitted storage operation is not normally the
generator of the waste. The owner or operator of the
storage operation does not possess the same knowledge
of the waste as the generator and does not maintain the
same control over what is placed in the packages as the
original generator. In addition, safeguards are
necessary because P1MW is stored for varying lengths of
time and under varying conditions. (Tr2. at 165-75.)
Treatment (Subpart C)
This subpart applies to all facilities that treat P1MW to
eliminate its infectious potential.
P1MW may not be disposed of in Illinois unless it has been
treated in accordance with the standards of this subpart; the
standards apply whether the treatment occurred at a facility
located in Illinois or elsewhere (Section 1422.120).
At Section 1422.121 it is required that there be
certification of the treatment:
No person shall cause or allow the disposal of any P1MW
where the infectious potential has been eliminated by
treatment unless the treatment facility certifies to
the transporter, if other than the generator, and
certifies to the landfill operator or receiving
facility operator that the P1MW has been treated in
accordance with this Part, and, if applicable, with all
terms and conditions specified in its operating permit.
Data to verify the efficacy of the treatment unit shall
be made available to the receiving facility. No person
shall falsely certify that P1MW has been treated in
accordance with this Part.
Design and operating requirements for P1MW treatment
facilities occur in Section 1422.122. Subsections (a) and (b)
apply to all treatment facilities, including those that do not
require a permit. Requirements include proper management of
residues, filing of an annual report, and the cleaning and
Oit~3-i292
—31—
disinfection of the facility upon closure. Mechanical treatment
of P1MW is allowed only if it is an integral step in the
treatment process; this is to minimize the dispersion of airborne
particles (Tr2. at 33).
The (a) (1) portion of Section 1422.122 has undergone
particular evolution during the course of this proceeding.
1422.122(a) (1) is intended to provide an operational definition
of the statutory term “eliminates the infectious potential of the
waste”, which is critical to the whole concept of treatment of
P1MW. Initially in the Agency proposal and in the first notice
proposal the definition was attempted by directing the interested
person to Sections 1422.124 and 1422.125. By the time of second
notice, however, it was apparent that this device did not provide
very much useful instruction and moreover was a source of
confusion to at least some of the affected persons (see PC #35,
#36, and Second Notice Opinion at p. 17). Accordingly, at second
notice and at the recommendation of the National Solid Waste
Management Association (PC #36 at 3), the Board modified the
language in a manner that it thought to be consistent with the
whole of Part 1422.
The Agency later objected to the amendment of its favored
language and sought to have JCAR reinstate that language (see
discussion above). Reinstatement was not acceptable either to
other participants or the Board.
Today’s final subsection (a) (1) language is language adopted
by the Board on June 3, 1993 in its resolution responding to the
JCAR objection (see discussion above). The language continues to
provide an “upfront” operational definition of “eliminates the
infectious potential”, in addition to providing direction to the
testing procedures of Sections 1422.124 and 1422.125.
Subsection (c) of Section 1422.122 contains additional
requirements that apply to those treatment facilities for which a
permit is required. These include personnel training, a written
contingency plan, and a written operating record to be kept at
the facility.
Section 1422.123 contains standards for treatment units.
The emphasis is on performance standards rather than on
authorization of particular techniques or technologies. Most
fundamentally, the treatment unit must be designed and operated
to eliminate the infectious potential of P1MW (subsection
(a)(1)). It must also be operated in modes determined by
manufacturer’s specifications and under the same conditions that
are used in the efficacy demonstrations (subsections (a) (2) to
(a)(5)). The same level of treatment is required whether Agency
permits are required or not.
t•~t ~
1
u
~ — u
29
3
—32—
Subsection (b) of 1422.123 allows treatment units to be used
by treatment facilities not required to have permits if the unit
meets certain requirements of the subsection or if the Board has
granted an adjusted standard.
A principle underlying the Section 1422.123(b) provisions
has been to allow for easy consideration of new technologies that
do not fit the definition of chemical, thermal, or irradiation
treatment. To achieve this end, participants and the Board have
addressed these provisions in some detail, with resolution not
achieved until second notice (see second notice opinion at pages
18—21)
The Initial Efficacy Test requirements are set out in
Section 1422.124, with supporting materials present in Section
1422.Appendix A. The Initial Efficacy Test is a one-time
demonstration made for each model of a particular treatment unit
that demonstrates that the unit will achieve a 6-log reduction of
all vegetative microorganisms. (Tr2. at 34.) If the Initial
Efficacy Test is undertaken by the unit’s manufacturer or some
person other than the treatment facility, the treatment facility
is responsible for obtaining and making available for inspection
at any time documentation of the test.
Section 1422.125, supported by Section l422.Appendix B, sets
out the requirements of the Periodic Verification Tests. These
are tests that are designed to be performed on an ongoing basis
to ensure that treatment efficacy continues.
Section 1422.126 sets out those conditions, in addition to
elimination of infectious potential, that are necessary.before a
sharp may be landfilled.
Section 1422.127 also allows the Agency to issue an
experimental treatment permit for a period of up to two years,
renewable once. Experimental permits are for processes or
techniques that do not otherwise satisfy the standards of Subpart
C. Residues from a treatment unit with an experimental permit
may or may not be considered P1MW, depending on the experimental
permit conditions.
ECONOMIC IMPACT
The Board is charged under the Act to take into account the
technical feasibility and economic reasonableness of all
regulatory proposals before it. (Act at Section 27(a).)
Compliance can be achieved with existing technology, so the
technical feasibility of reducing this type of pollution is not
an issue in this proceeding. Therefore, by this discussion the
Board examines the economic reasonableness of reducing this
‘11~
~
~
U
—33—
particular type of pollution by considering the information
presented in the record on this topic.
In general, a small percentage of the testimony and comments
address economic matters. A summary of that information is given
below.
Affected Facilities and Costs
The record contains information on the facilities that
generate medical waste as approximately: 2,500 health care
facilities (including hospitals, long term care facilities, local
health clinics), 24,000 physicians, 6,500 dentists43, and 3,906
funeral directors. (Report to the Governor, Exh. 5 at 10,
appendix 2). It is estimated that 103 Illinois colleges have
programs that potentially generate medical waste. (Exh. 37 Att.
16). The Agency submitted a 63 page list of 1400 special waste
haulers that may or may not opt to haul medical waste. A list of
haulers who contacted the Agency requesting information on the
requirements of commercial transportation of P1MW prior to
submittal of the proposal was also included in the record (See,
Exh. 37 Atts. 11 and 12). The Agency also states that there are
currently seven off—site transfer/storage/treatment facilities
permitted for P1MW by the Bureau of Land. There are 191 hospital
incinerators and 148 sites and 88 ethylene oxide units at 56
sites currently permitted by the Bureau of Air. (See, Exh. 37
Atts. 14 and 15). All these facilities and businesses are
estimated to be affected to some degree by these rules.
The Report to the Governor discusses costs of P1MW disposal
as follows:
The Study Group recognized the problem of escalating
health care costs and the increasing difficulty of
access to health care. It is the intent of the Study
Group that the effect of waste handling on health care
costs be limited as much as possible.
The cost to dispose of P1MW in Illinois depends on
several factors and obviously will vary within the
state. However, based on the waste management
companies polled, a common pricing arrangement is to
charge larger generators, such as hospitals, on a per
pound basis and the smaller ones per pickup or per
carton. A common conversion in comparing the weight
and volume of P1MW is 4.5 to 5.0 pounds/cubic foot.
***
~ Robert A. Rechner, Illinois Dental Association, estimates
that 7,000 dentists practice in Illinois. (Exh. 41).
01
L~.3-0295
—34—
A May 1989 American Hospital Association estimate
placed the range of costs for P1MW disposal for a 200
bed hospital to be between $63,000 and $173,000 per
year. Other factors could increase costs such as the
recent Clean Air Act amendments, regulatory changes,
etc.
(Exh. 5).
Throughout the hearing, members of the Study Group urged the
Board to be sensitive to costs. (Exh 45 at 7; Tn. at 109).
In addition, the NSWMA submitted a document it entitled an
Economic Impact Analysis. NSWMA states that its intent and that
of the Medical Waste Tracking Study Group has been to minimize
cost impact the health care community in developing these
regulations. NSWMA states that the P1MW regulations will have
little appreciable economic impact on currently regulated
hospital generators. Although the P1MW regulations will expand
the scope of generators regulated beyond the hospitals currently
regulated, NSWMA states that these generators “should be able to
reduce the collection fee and treatment cost burden by employing
one of the several on—site treatment options, or by transporting
the limited quantity of P1MW they generate to a hospital with
which they are affiliated for treatment. NSWMA estimates that 40
to 50 of these newly regulated small quantity generators will be
able to utilize on-site or off—site hospital treatment.” (Exh.
37 Att. 10).
NSWMA gives other estimates of economic impact as follows
(a.):
The economic impact for the estimated remaining 17,500
generators, who select commercial management of P1MW,
should be negligible for two reasons. First, P1MW is
defined by the new regulations in a way that permits
generators to be more selective in the types of waste
requiring P1MW management. Overall, this should reduce
the volume of P1MW. Second, increased competition has
reduced the cost for commercial P1MW management, and
this trend should continue.
Finally, NSWMA estimates that efficient waste segregation,
increased competition, and increased employee safety and
awareness should all serve to reduce costs. (Exh. 37 Att. 10).
Robert A. Rechner of the Illinois Dental Society estimated
that the costs of purchasing sharps containers and outer
packages, and the pick—up fee increases costs to dentists
approximately $25.00 per month. He also estimated that the
periodic verification tests, assuming the tests were conducted
monthly for one autoclave for 2 dentists in the state would
I, •:~
.
7
—35—
result in costs of $4,410,000 for all the dentists in the state.
(Exh. 41).
Cost-Benefit Analysis
The benefit to the rule, put most simply, is the lessening
of the public health risks of infection from medical waste. The
information in the record indicates that the costs associated
with today’s regulations have been minimized to the extent
possible.
In addition to the discussion above, it is worth noting that
the costs of these rules would be additionally offset when
compared with similar programs already in place at health care
facilities. The Agency states that OSHA’s Occupational Exposure
to Bloodborne Pathogens Rule (29 CFR 1910.1030 (1991)) (Exh. 37
Att. 6) contains requirements for segregation, packaging,
labeling, marking, transportation, storage, and treatment of
regulated medical waste that meets or exceeds the requirements
for these rules. (Exh. 37 at 3).
The Board has considered the information in the record
pertaining to the economic reasonableness of these rules,
including comments, testimony, and exhibits. Actual dollar
figures of the costs associated with these rules has been
difficult to ascertain from the record. However, the Board
concludes that the record supports the finding that the instant
rule will not be economically unreasonable.
U
I 4
~:)
* u
—36—
ORDER
The Clerk of the Board is directed to submit the text of the
following regulations to the Secretary of State for final notice
pursuant to Section 6 of the Administrative Procedure Act.
TITLE 35: ENVIRONMENTAL PROTECTION
SUBTITLE M: BIOLOGICAL MATERIALS
CHAPTER I: POLLUTION CONTROL BOARD
SUBCHAPTER b: POTENTIALLY INFECTIOUS MEDICAL WASTES
PART 1420
GENERAL PROVISIONS
Section
1420.101 Scope and Applicability
1420. 102 Definitions
1420.103 Incorporations by Reference
1420.104 Prohibitions
1420.105 Permit and Manifest Requirements and Exceptions
1420.106 Penalty Factor
1420.107 Cleaning and Disinfection
1420.120 Severability
AUTHORITY: Implementing and authorized by Section~56.2-fe)- and
~ of the Environmental Protection Act (Ill. Rev. Stat. 19&9~9~,
ch. 111 1/2, par~.1056.2(c),
go
addcd by P.A. 87-752 cffcotivc
January 1, 1992. as amended by P.A. 87—1097. effective January 1,
1993, and 1027) 1415 ILCS 5/56.2 and 271.
SOURCE: Adopted in R91-19, at 16 Ill. Reg. 2594, effective
February 3, 1992; amended in R91-20, at
_____
Ill. Reg.
effective ______________________
NOTE: Capitalization denotes statutory language.
1420.101 Scope and Applicability
a3-This Subtitle applies to all persons who generate, transport,
treat, store,- or dispose of potentially infectious medical waste.
It sets forth standards for such activities occurring in whole or
in part within the State of Illinois.
z)
~nii~Lz1rt QCt3
iortn
act iflJ~iOflQ ~ ~
thio Cubti~’~cxcc’-4-
-~r
-‘-coifically providcd
othcrwicic.
~
~~
ropcal pro-exiBting rulca for handling modioalwaGtea
by January 1, 1992. Section 56.2(c) requires the Board
to adopt by January 1, 1992 a li3t of Claoa 4 otiologic
(1 1
I
1:
•~-I
~ —
U~~J
r~2 Q~
—37—
agonto, which lendo operative mean
waste,” ao that term is used in the statutory
definition of potentially infectious medical wacte at
Section 3.81. Section 56.2(a) and (a) require the
Board to adopt standards for the tranoportation,
packaging, segregation, labelling, and marking of
potentially infectious medical waste by January 1,
1993. Section 56.2(f) authori~eoadditional rules to
promote the purposes of Title XV of the Environmental
Protection Act (Ill. Rev. Stat. 1989 oh. 111~,par.
1001 et sag., as amended by P.A. 87-752, affective
January 1, 1992).
(Source: Amended at 17 Ill. Reg.
__________________,
effective
Section 1420.102 Definitions
All definitions set forth in this Section shall have the
following meanings throughout this Subtitle, unless specifically
provided otherwise. Words and terms not defined have the
meanings set forth in the Act.
“6—log reduction” means a 6 decade reduction or a one
millionth (0.000001) survival probability in a
microbial population.
“Act” means the Environmental Protection Act (Ill. Rev.
Stat. 1989~j~,ch. 111 1/2, par. 1001 et seq., as
amended by P.A. 87—1097. effective January 1. 1993 752
and P.A. 87-650, both offootive January 1, 1992) 415
ILCS 5/1 et sep.1.
“Agency” means the Illinois Environmental Protection
Agency.
“ATCC” means American Type Culture Collection.
“Board” means the Illinois Pollution Control Board.
“CFU” means colony forming unit.
“Chemical treatment” means the treatment of P1MW in a
unit that uses disinfectants or chemicals as the
primary means to eliminate the infectious potential of
the waste. Examples of chemical treatment are ethylene
oxide, chlorine and ozone.
“Class 4 etiologic agent” means a pathogenic agent that
is extremely hazardous to laboratory personnel or that
may cause serious epidemic disease. Class 4 etiologic
agent includes the following viral agents:
U I
L~3-O299
—38—
Alastrim, Smallpox, Monkey pox, and Whitepox (when
used for transmission or animal inoculation
experiments)
j..
Hemorrhagic fever agents (including Crimean
hemorrhagic fever (Congo), Junin, and Machupo
viruses, and other~not yet defined)~
Herpesvirus simiae (Monkey B virus)~
Lassa virusl
Marburg virusj
Tick-borne encephalitis virus complex (including
Absettarov, Hanzalova, HYPR, Kumlinge, Russian
spring—summer encephalitis, Kyasanur forest
disease, Omsk hemorrhagic fever, and Central
European encephalitis viruses)~
Venezuelan equine encephalitis virus (epidemic
strains, when used for transmission or animal
inoculation experiments) ~
Yellow fever virus (wild, when used for
transmission or animal inoculation experiments).
BOARD NOTE: A Class 4 Agent helps define an
“isolation waste” for the purposes of Section
3.81~4(a)(6) of the Act and this Subtitle. This
listing derives from the CDC document,
“Classification of Etiologic Agents on the Basis
of Hazard,” and is supplemented from the CDC/NIH
document “Biosafety in Microbiological and
Biomedical Laboratories.”
“Container” means a receptacle that does not contain
P1MW.
“Detergent” means a cleansing substance that contains
surface—active agents for rapid wetting, penetration,
and emulsification of fats and oils, plus a
seauestering agent.
“Detergent—sanitizer cleaner” means an a~entthat is
both a detergent and sanitizer. The sanitizer must be
registered by the United States Environmental
Protection Agency, as identified on its label.
“Discharge” means the accidental or intentional
spilling, leaking, pumping, pouring, emitting, emptying
or dumping of waste into or on any land or water. This
r~i
~,
‘
—39—
does not include the normal loading and unloading of
P1MW from a vehicle.
“Enclosed compartment” means a compartment that
provides protection from the elements. prevents
sDillage and Prevents containers from falling of f the
vehicle. The enclosed compartment cannot be used to
meet the packaging reguirements of 35 Ill. Mm. Code
1421.Subpart C.
“Equivalent ba kill” (T) means the logarithm of the
indicator microorganisms that must be killed and
correlates, at a minimum, to a 6—log reduction of
viable test microorganisms.
“HIGHLY COMMUNICABLE DISEASE” MEANS THOSE DISEASES
IDENTIFIED AS CLASS 4 ETIOLOGIC AGENTS under this Part.
(Section 3.8~4(a)(6) of the Act)
“Indicator microorganisms” means those microorganisms
listed in 35 Ill. Adm. Code 1422.A~pendixA. Table B.
as classified bY ATCC.
“International biohazard symbol” means the symbol that
is shown in 35 Ill. Adm. Code 1421.Illustration A.
“Irradiation treatment” means the treatment of P1MW in
a unit that uses ionizing radiation as the primary
means to eliminate the infectious potential of the
waste. Examples of irradiation treatment are aamma
(cobalt 60) and electron beam.
‘~XSOLATION WASTE”
MEANS DICCABDED WASTE MATERIALS
CONTAMINATED WITH BLOOD, EXCRETIONS, EXUDATEC,
AND
SECRETIONS FROM HUMANS THAT
ARE
ICOLATED TO PROTECT
OTHERS FROM HICHLY
COMMUNICABLE
DICEASEC.
(Ceotion
3.81(a) (6) of the Act)
“Log” means logarithm to the base ten (10).
“Loa kill” (L) means the difference
between the
logarithms of viable test microorganisms or indicator
microorganisms before and after treatment.
“Oversized P1MW” means a single waste item that is too
Larae to be placed into a thirty-three (33) gallon baa
or container.
“Package” means a receptacle that contains P1MW.
“PFU” means ~laaue forming unit.
01 ~43O3OI
—40—
“PERSON” IS
ANY
INDIVIDUAL. PARTNERSHIP. CO-
PARTNERSHIP. FIRM. COMPANY. CORPORATION. ASSOCIATION,
JOINT STOCK
COMPANY.
TRUST. ESTATE. POLITICAL
SUBDIVISION, STATE AGENCY. OR ANY
OTHER
LEGAL ENTITY,
OR THEIR REPRESENTATIVE, AGENT. OR ASSIGNS.
(Section
3.26 of the Act)
“POTENTIALLY INFECTIOUS MEDICAL WASTE” or
“P1MW”
MEANS
THE FOLLOWING TYPES OF WASTE GENERATED IN CONNECTION
WITH THE DIAGNOSIS, TREATMENT (I
.
E
•,
PROVISION OF
MEDICAL SERVICES), OR IMMUNIZATION OF HUMAN BEINGS OR
ANIMALS; RESEARCH PERTAINING TO THE PROVISION OF
MEDICAL SERVICES; OR THE PROVISION OR TESTING OF
BIOLOGICALS:
Ar4irv~L WA~im;
CULTURES AND
CTOCKC;
HUMAN ~vuu Ariu ~uuu PRODUCTC;
HUMAN
PATHOLOCICAL WASTES;
i~uLariu1~1
~IACTE~*
ArlIJ
UHUCED SHARPS.
USED CHARrC;
CULTURES AND STOCKS.
THIS WASTE SHALL INCLUDE BUT
NOT BE LIMITED TO CULTURES
AND
STOCKS OF AGENTS
INFECTIOUS TO HUMANS. AND ASSOCIATED BIOLOGICALS;
CULTURES FROM MEDICAL OR PATHOLOGICAL
LABORATORIES; CULTURES AND STOCKS OF INFECTIOUS
AGENTS FROM RESEARCH AND INDUSTRIAL LABORATORIES;
WASTES FROM THE PRODUCTION OF BIOLOGICALS;
DISCARDED LIVE OR ATTENUATED VACCINES: OR CULTURE
DISHES AND DEVICES USED TO TRANSFER. INOCULATE, OR
MIX CULTURES.
HUMAN PATHOLOGICAL WASTES. THIS WASTE SHALL
INCLUDE TISSUE. ORGANS. AND BODY PARTS (EXCEPT
TEETH AND
THE CONTIGUOUS STRUCTURES OF BONE
AND
GUM). BODY FLUIDS THAT ARE
REMOVED DURING SURGERY.
AUTOPSY. OR OTHER MEDICAL PROCEDURES; OR SPECIMENS
OF BODY FLUIDS AND THEIR CONTAINERS.
HUMAN BLOOD AND BLOOD PRODUCTS. THIS WASTE SHALL
INCLUDE DISCARDED HUMAN BLOOD, BLOOD COMPONENTS
(e.g.
SERUM AND PLASMA)
•
OR SATURATED MATERIAL
CONTAINING FREE FLOWING BLOOD OR BLOOD COMPONENTS.
0 IL~-O3O2
t
—41—
USED SHARPS. THIS WASTE
SHALL INCLUDE
BUT
NOT BE
LIMITED TO DISCARDED SHARPS USED IN
ANIMAL OR
HUMAN PATIENT CARE. MEDICAL RESEARCH, OR CLINICAL
OR PHARMACEUTICAL LABORATORIES; HYPODERMIC,
INTRAVENOUS. OR OTHER MEDICAL NEEDLES; HYPODERMIC
OR INTRAVENOUS SYRINGES; PASTEUR PIPETTES; SCALPEL
BLADES; OR BLOOD VIALS.
THIS WASTE SHALL ALSO
INCLUDE BUT NOT BE LIMITED TO OTHER TYPES OF
BROKEN OR UNBROKEN GLASS (INCLUDING SLIDES
AND
COVER SLIPS) IN CONTACT WITH INFECTIOUS AGENTS.
ANIMAL
WASTE. ANIMAL WASTE MEANS DISCARDED
MATERIALS, INCLUDING CARCASSES, BODY PARTS. BODY
FLUIDS. BLOOD. OR BEDDING ORIGINATING FROM ANIMALS
INOCULATED DURING RESEARCH
•
PRODUCTION OF
BIOLOGICALS. OR PHARMACEUTICAL TESTING WITH AGENTS
INFECTIOUS TO HUMANS.
ISOLATION WASTE.
THIS WASTE SHALL INCLUDE
DISCARDED MATERIALS CONTAMINATED WITH BLOOD,
EXCRETIONS. EXUDATES, AND SECRETIONS FROM HUMANS
THAT ARE ISOLATED TO PROTECT OTHERS FROM HIGHLY
COMMUNICABLE DISEASES. “HIGHLY COMMUNICABLE
DISEASES” MEANS THOSE DISEASES IDENTIFIED BY THE
BOARD IN RULES ADOPTED UNDER SUBSECTION (e) OF
SECTION 56.2 of the ACT. (See Section 1420.102 of
this Part)
UNUSED
SHARPS. THIS WASTE SHALL INCLUDE
BUT NOT
BE LIMITED TO THE FOLLOWING UNUSED. DISCARDED
SHARPS: HYPODERMIC,
INTRAVENOUS. OR OTHER
NEEDLES: HYPODERMIC OR INTRAVENOUS SYRINGES: OR
SCALPEL BLADES.
POTENTIALLY INFECTIOUS MEDICAL WASTE DOES NOT
INCLUDE THE FOLLOWINC:
WASTE GENERATED AS GENERAL HOUSEHOLD WASTE;
WASTE (EXCEPT FOR SHARPS) FOR WHICH THE
INFECTIOUS POTENTIAL HAS
BEEN ELIMINATED BY
TREATMENT; OR
SHARPS THAT MEET BOTH OF THE FOLLOWING
CONDITIONS:
THE INFECTIOUS POTENTIAL HAS BEEN
ELIMINATED FROM THE SHARPS BY TREATMENT;
AND
fl I h
—
11
‘)
—42—
THE SHARPS ARE RENDERED UNRECOGNIZABLE
BY TREATMENT. (Section 3.8&j of the
Act)
“Putrescence” means the partial decomposition of
organic matter by microorganisms so as to cause
malodors. aases or other offensive conditions, or that
is capable of providing food for vectors.
“Registered professional engineer” means a Person
registered
under the Illinois
Professional
Engineering
Practice Act (Ill. Rev. Stat. 1991. ch. 111, par. 5201
et sea.) 225 ILCS 325/1
et seg.1.
“Reusable container” means a receptacle that meets the
requirements of 35 Ill. Adm. Code 1421.121(a) and (b);
is made and repaired with materials that are corrosion
resistant and non-absorbent; and designed and
constructed so as to easily permit cleaning and
disinfection in accordance with Section 1420.107 of
this Subtitle. A reusable container is not a
single—use container or is not made of cardboard.
“Sanitizer” means an antimicrobial aaent that is
intended for application to inanimate obiects or
surfaces for the purpose of reducing the microbial
count to safe levels. The sanitizer must be registered
by the United States Environmental Protection Agency,
as identified on its label.
“Sharps” mean unused sharps and used sharps as stated
in the definition of potentially infectious medical
waste in this Section with or without residual fluids.
“Significant mechanical change” means the substitution
or addition of mechanical parts that result in
different operating conditions. A significant
mechanical chanae does not mean the replacement of a
part(s) that meets the same specifications p~ the
original part.
“Single—use container” means a container intended by
the manufacturer for one use only, such as biohazard
bags.
“SITE” MEANS ANY LOCATION. PLACE, TRACT OF LAND. AND
FACILITIES. INCLUDING BUT NOT LIMITED TO BUILDINGS. AND
IMPROVEMENTS USED FOR PURPOSES SUBJECT TO REGULATION OR
CONTROL BY THE ACT OR REGULATIONS THEREUNDER. (Section
3.43 of the Act) For the ~ur~ose of this Subtitle,
each campus of an educational institution is considered
to be
a single site.
q
—
—43—
“STORAGE”
MEANS
THE CONTAINMENT OF WASTE, EITHER ON A
TEMPORARY
BASIS OR FOR
A PERIOD OF YEARS.
IN
SUCH A
MANNER AS NOT TO CONSTITUTE DISPOSAL. (Section
3.46 of
the Act)
“STORAGE SITE” means A SITE AT WHICH WASTE IS STORED.
“STORAGE SITE” INCLUDES TRANSFER STATIONS. (Section
3.47 of the Act)
“Test microoraanisms” means those microorganisms listed
in_Section 1422.Appendix A, Table A. as classified by
ATCC.
“Thermal treatment” means the treatment of P1MW in a
unit that uses elevated temperatures as the Primary
means to eliminate the infectious potential of the
waste. Examples of thermal treatment are incineration~.
steam sterilization. microwaving. radiowavina. infrared
heating, pyrolysis. plasma systems and baser
treatments.
“TRANSFER STATION” MEANS A SITE OR FACILITY THAT
ACCEPTS WASTE FOR TEMPORARY STORAGE OR CONSOLIDATION
AND
FURTHER TRANSFER TO A WASTE DISPOSAL. TREATMENT OR
STORAGE FACILITY.
“TRANSFER STATION” INCLUDES A SITE
WHERE WASTE IS TRANSFERRED FROM (1) A RAIL CARRIER TO A
MOTOR VEHICLE OR
WATER CARRIER; (2)
A WATER CARRIER TO
A RAIL CARRIER OR
MOTOR VEHICLE: (3) A MOTOR VEHICLE TO
A
RAIL
CARRIER. WATER CARRIER OR MOTOR
VEHICLE; (4) A
RAIL CARRIER TO A RAIL CARRIER. IF THE WASTE
IS REMOVED
FROM A RAIL CAR; OR (5) A WATER CARRIER TO A WATER
CARRIER. IF THE WASTE IS REMOVED FROM A VESSEL.
(Section 3.83 of the Act)
“TREATMENT” MEANS ANY
METHOD. TECHNIQUE OR PROCESS,
INCLUDING NEUTRALIZATION. DESIGNED TO CHANGE THE
PHYSICAL. CHEMICAL. OR BIOLOGICAL CHARACTER OR
COMPOSITION OF ANY WASTE SO AS TO NEUTRALIZE IT OR
RENDER IT NONHAZARDOUS. SAFER FOR TRANSPORT. AMENABLE
FOR_RECOVERY. AMENABLE FOR STORAGE. OR REDUCED IN
VOLUME. SUCH TERM INCLUDES ANY ACTIVITY OR PROCESSING
DESIGNED TO CHANGE THE PHYSICAL FORM OR CHEMICAL
COMPOSITION OF HAZARDOUS WASTE SO AS TO RENDER IT
NONHAZARDOUS. (Section 3.49 of the Act)
“Unrecognizable” means relating to a sharp that has
undergone physical alteration (e.g., melting. charring,
corroding, or grinding) so that the sharp may no lonaer
be used for its intended purpose.
0! L~3-O305
—44—
“Vector” means any living agent. other than human.
capable
of transmitting, directly or
indirectly, an
infectious disease.
“Vehicbe” means any device used to transport special
waste in bulk or in packages. tanks or other
containers.
(Source:
Amended at 17 Ill. Reg.
)
effective
Section 1420.103
Incorporations by
Reference
The following materials are incorporated by reference. This
Section incorporates no later editions or amendments.
Standard Methods for the Examination of Water and
Wastewater. American Public Health Association et
p1.
(1015 Fifteenth Street, N.W.. Washinaton, D.C. 20005)
(18th Edition, 1992).
Test Methods for Evaluating Solid Waste.
Physical/Chemical Methods. EPA Publication SW-846
(Third Edition. 1986 as amended by Uødate I (November.
1990)). SW—846 and UPdate I are available from the
Superintendent of Documents. U.S. Government Printing
Office. Washington. D.C. 20402. (202) 783—3238.
(Source: Added at 17 Ill. Reg
effective
Section 1420.104
Prohibitions
NO PERSON SHALL:
CAUSE OR ALLOW
THE DISPOSAL OF
ANY P1MW. SHARPS MAY BE
DISPOSED OF IN ANY LANDFILL PERMITTED BY THE AGENCY
UNDER SECTION 21 OF the ACT TO ACCEPT MUNICIPAL WASTE
FOR DISPOSAL. IF BOTH:
fl
THE
INFECTIOUS POTENTIAL HAS BEEN ELIMINATED FROM
THE SHARPS BY TREATMENT; AND
~j THE SHARPS
ARE PACKAGED IN ACCORDANCE WITH Part
1421, Subpart
C of this Subtitle.
CAUSE OR
ALLOW THE DELIVERY OF ANY P1MW
FOR TRANSPORT
STORAGE. TREATMENT OR TRANSFER EXCEPT IN ACCORDANCE
WITH
Part 1421,Subpart C of this Subtitle.
gj. BEGINNING JULY 1. 1992,
CAUSE OR ALLOW THE DELIVERY OF
ANY P1MW
TO A PERSON OR FACILITY FOR STORAGE.
ç~
i
I
;,
~~$\J~J
~
—45—
TREATMENT. OR TRANSFER THAT DOES NOT HAVE A PERMIT
IS SUED
BY
THE AGENCY TO RECEIVE P1MW pursuant to
Section 39 of the Act. UNLESS NO PERMIT IS REQUIRED
pursuant to subsection 1420.105(c) of this Part.
~j BEGINNING
JULY
1. 1992. CAUSE OR ALLOW THE DELIVERY OR
TRANSFER
OF ANY P1MW FOR TRANSPORT UNLESS:
fl-
THE TRANSPORTER HAS A PERMIT ISSUED
BY THE AGENCY
TO
TRANSPORT P1MW.
OR THE TRANSPORTER IS EXEMPT
FROM THE PERMIT REQUIREMENT pursuant to subsection
1420.105(b) of this Part. Permit applications
must be submitted on forms provided by the Agency.
21
A P1MW MANIFEST IS COMPLETED FOR THE WASTE unless
no manifest is reauired pursuant to subsection
1420.105(e) of this Part.
~j CAUSE OR ALLOW THE ACCEPTANCE OF ANY P1MW FOR
PURPOSES
OF TRANSPORT, STORAGE. TREATMENT.
OR
TRANSFER
EXCEPT IN
ACCORDANCE WITH Part 1421. Subpart C of this Subtitle
and Part 1422. Subpart B of this Subtitle.
~j BEGINNING JULY 1, 1992. CONDUCT ANY P1MW TRANSPORTATION
OPERATION:
fl
WITHOUT A PERMIT ISSUED BY THE AGENCY TO TRANSPORT
P1MW. unless no permit is reauired pursuant to
subsection 1420.105(b) of this Part.
21
IN VIOLATION OF ANY CONDITION OF ANY PERMIT ISSUED
BY THE AGENCY UNDER the ACT.
~
IN VIOLATION OF ANY REGULATION ADOPTED BY THE
BOARD.
4j
IN VIOLATION OF ANY ORDER
ADOPTED BY THE BOARD
UNDER the ACT.
gj BEGINNING JULY 1. 1992, CONDUCT ANY P1MW TREATMENT.
STORAGE,
OR TRANSFER OPERATION:
~j WITHOUT A PERMIT ISSUED BY THE AGENCY THAT
SPECIFICALLY AUTHORIZES THE TREATMENT, STORAGE. OR
TRANSFER OF P1MW pursuant with Section 39 of the
Act, unless no permit is reauired pursuant to
subsection 1420.105(c) of this Part. Permit
applications must be submitted on forms provided
by the Agency.
21
IN VIOLATION OF ANY CONDITION OF ANY PERMIT ISSUED
BY THE AGENCY UNDER the ACT.
0
L43-03Q7
—46—
.~J..
IN VIOLATION OF ANY REGULATIONS ADOPTED
BY THE
BOARD.
~j..
IN VIOLATION OF
ANY
ORDER ADOPTED BY THE BOARI)
UNDER the ACT.
~
TRANSPORT
P1MW
UNLESS THE TRANSPORTER CARRIES A
COMPLETED
P1MW MANIFEST,
unless no
manifest is reauired
pursuant to subsection 1420.105(e)
of this Part.
LL
OFFER FOR TRANSPORTATION.
TRANSPORT. DELIVER. RECEIVE
OR ACCEPT
P1MW FOR WHICH A MANIFEST IS REQUIRED. UNLESS
THE MANIFEST
INDICATES THAT THE FEE
REQUIRED UNDER
SECTION 56.4 OF the ACT HAS BEEN PAID.
jj. BEGINNING JANUARY 1, 1994. CONDUCT A P1MW TREATMENT
OPERATION AT AN INCINERATOR IN EXISTENCE ON THE
EFFECTIVE DATE OF THIS TITLE IN VIOLATION OF EMISSION
STANDARDS ESTABLISHED FOR THESE INCINERATORS UNDER
SECTION 129 OF THE CLEAN AIR ACT (42 USC 7429)
•
AS
AMENDED. (Section 56.1 of the Act)
~çJ Cause or allow the discharge of P1MW from a vehicle.
fl
Cause or allow the discharge of P1MW into a sanitary or
combined sewer except in accordance with 35 Ill. Adm.
Code: Subtitle C. No person shall cause or allow the
discharge of inert or solid P1MW. or inert or solid
materials resubtina from the treatment of P1MW. into
any sanitary sewerage system. combined sewerage system.
or storm sewerage system directly or indirectly
tributary to waters of the State. Such prohibition
applies to. but is not limited to. absorbents, aluminum
or other metallic foils, ash, bone, bedding materials.
cellulose, culture dishes, aarments and other cloth
materials, gauze, glass, pads, plastic, sharps.
shavinas. straw and syringes.
BOARD NOTE: Interested persons should note that
discharges to sewer systems can also be regulated by
units of local government.
(Source: Added at 17 Ill. Reg.
,
effective
________________________________________________________________________________________)
1420.105 Permit and Manifest Reauirements and
Exceptions
~j The permit and permit appeal provisions of Sections 39
and 40 of the Act and Board regulations adopted
thereunder aPPly to this Subtitle.
UI i~3-O308
—47—
~ A person who conducts a P1MW transportation operation
is required to obtain a P1MW
hauling permit from the
Aaency. except:
~
A PERSON TRANSPORTING P1MW
GENERATED SOLELY BY
THAT
PERSON’S ACTIVITIES; OR
21 NONCOMMERCIAL TRANSPORTATION OF LESS
THAN 50
POUNDS OF POTENTIALLY INFECTIOUS MEDICAL WASTE AT
ANY ONE TIME; OR
~ ThE U.S. POSTAL SERVICE. (Section 56.1(f) of the
Act)
~ A person who conducts a P1MW treatment, storaae, or
transfer operation is reauired to obtain a permit from
the Agency, except:
il ANY PERSON CONDUCTING A P1MW TREATMENT. STORAGE.
OR TRANSFER OPERATION
FOR
P1MW GENERATED BY THE
PERSON’S
OWN
ACTIVITIES THAT ARE TREATED, STORED,
OR TRANSFERRED WITHIN THE SITE WHERE THE P1MW IS
GENERATED; OR
21 ANY HOSPITAL THAT TREATS.
STORES. OR TRANSFERS
ONLY P1MW GENERATED BY ITS OWN ACTIVITIES OR BY
MEMBERS OF ITS MEDICAL STAFF. (Section 56.1(a) of
the Act) If the transportation of P1MW is
interrupted so as not to constitute storage, no
permit is required under Section 56.1(a) of the
Act. For example. transportation of P1MW
interrupted by vehicle repairs or inclement
weather does not constitute storaae.
~ A person applying for a permit for a P1MW treatment.
storage. or transfer operation shall file an
application with the Agency in accordance with the
requirements and procedures of 35 Ill Adm. Code
1422.105 through 1422.107.
~j Any Person who transports P1MW is required to carry a
completed P1MW manifest excePt for the transportation
of:
fl P1MW BEING TRANSPORTED BY GENERATORS WHO GENERATED
THE WASTE BY THEIR OWN ACTIVITIES. WHEN THE P1MW
IS TRANSPORTED WITHIN OR BETWEEN SITES OR
FACILITIES OWNED. CONTROLLED. OR OPERATED BY THAT
PERSON: OR
21 LESS THAN 50 POUNDS OF P1MW AT ANY ONE TIME FORE A
NONCOMMERCIAL TRANSPORTATION ACTIVITY; OR
01 L3-03O9
—48—
~j. P1MW BY THE U.S. POSTAL SERVICE. (Section 56.1(h)
of the Act)
(Source: Added at 17 Ill. Reg.
,
effective
F
Section 1420.106 Penalty Factor
IN MAKING ITS ORDERS AND DETERMINATIONS RELATIVE TO PENALTIES. IF
ANY. TO BE IMPOSED FOR VIOLATING SECTION 56.1(a) OF the ACT. THE
BOARD, IN ADDITION TO THE FACTORS IN SECTIONS 33(c) AND 42(h) OF
the ACT. OR THE COURT SHALL TAKE INTO CONSIDERATION WHETHER THE
OWNER OR OPERATOR OF THE LANDFILL REASONABLY RELIED ON WRITTEN
STATEMENTS FROM THE PERSON GENERATING OR TREATING THE WASTE THAT
THE WASTE IS NOT POTENTIALLY INFECTIOUS MEDICAL WASTE.
(Section
56.1(k)
of the Act)
(Source: Added at 17 Ill. Reg.
,
effective
Section 1420.107 Cleaning and Disinfection
~j Cleaning and disinfection comprises:
~j. Washing with a solution of detergent used in
accordance with manufacturer’s instructions and
agitation to remove visible contamination from
each surface, followed by a clean water rinse; and
21. One of the following methods of low-level
disinfection:
~j ExPosure to hot water of at least 82 dearees
Centigrade (180 degrees Fahrenheit) for a
minimum of fifteen (15) seconds
~ Rinsing with. or immersion in, a chemical
disinfectant registered by the United States
Environmental Protection AgencY. as
identified on its label and used in
accordance with the manufacturer’s
instructions
~j Rinsing with, or immersion in. a hy~ochborite
solution at a concentration of 50 ppm. For
example. 1/8 cup of common household bleach
(5.25 sodium hvpochlorite) per aablon of ta~
water (31 milliliters bleach to 3.78 liters
of water); or
tfl4JUi
‘~
—49—
P1 Other
disinfection
processes as approved by
the Agency in writing as an eauivalent
to one
of the methods in subsections (a) (2) (A)
and
(B) of this Section.
~J A detergent—sanitizer used in coniunction with
agitation to remove visible contamination maY be
substituted for the methods in subsection (a) of this
Section, if used in accordance with the manufacturer’s
instructions.
(Source: Added at 17 Ill. Reg.
,
effective
Section 1420.120 Severability
If anY Section. subsection. sentence or clause of this Subtitle
is
adludaed unconstitutional, invalid or otherwise not effective
for anY reason, such adludication does not affect the validity of
this Subtitle as a whole or of any Section. subsection, sentence
or clause thereof not adiudged unconstitutional, invalid or
otherwise not effective for any reason.
(Source: Added at 17 Ill. Req.
_____
,
effective
0ii;3~O3JI
—50—
TITLE 35:
ENVIRONMENTAL PROTECTION
SUBTITLE M:
BIOLOGICAL MATERIALS
CHAPTER I:
POLLUTION CONTROL BOARD
SUBCHAPTER b:
POTENTIALLY INFECTIOUS MEDICAL WASTES
PART 1421
ACTIVITY STANDARDS
SUBPART A: GENERAL PROVISIONS
Section
1421.101 Compliance Dates
SUBPART B: SEGREGATION
Section
1421.110 Scope and Applicability
1421.111 Standards and Criteria
SUBPART C:
PACKAGING
Section
1421.120 Scope and Applicability
1421.121 Standards and Criteria
SUBPART D: LABELING
AND MARKING
Section
1421.130 Scope and Applicability
1421.131 Standards and Criteria
SUBPART E: TRANSPORTATION
Section
1421.140
Scope and Applicability
1421.141
Standards and Criteria
ILLUSTRATION A
International Biohazard Symbol
AUTHORITY: Implementing and authorized by Sections 56.2 and 27
of the Environmental Protection Act (Ill. Rev. Stat. 1991, ch.
111 1/2, pars. 1056.2 and 1027) 415 ILCS 5/56.2 and 27.
SOURCE: Adopted in R91-20, at
_____
Ill. Reg.
_______,
effective
NOTE: Capitalization denotes statutory language.
SUBPART A: GENERAL PROVISIONS
Section 1421.101 Compliance Dates
0k3-0312
—51—
Persons subject to this Part shall comply with its standards and
criteria by
____________________,
1993 (effective date).
SUBPART B:
SEGREGATION
Section 1421.110
Scope and
Applicability
This Subpart applies to
persons who generate or transport P1MW,
and to owners or operators of P1MW storage sites, transfer
stations and treatment facilities.
Section 1421.111 Standards and Criteria
a) Generators shall segregate P1MW as follows:
1) Sharps,
2) Oversized P1MW, and
3) All other.
b) P1MW mixed with other waste is regulated under this
Subtitle as P1MW and the mixture is not exempt from any
other applicable regulations.
c) This Section does not prohibit the placing of
previously segregated and properly packaged (in
accordance with Subpart C of this Part) sharps with
other waste, provided the mixture is managed in
accordance with subsection (b) of this Section.
SUBPART C: PACKAGING
Section 1421.120 Scope and Applicability
This Subpart applies to persons who package P1MW for off-site
transportation.
Section 1421.121 Standards and Criteria
a) P1MW, except for oversized P1MW, must be placed in a
container, or a combination of containers. Such
container must be:
1)
RIGID;
2) LEAK-RESISTANT;
3) IMPERVIOUS TO MOISTURE;
01
L~~3-O313
—52—
4)
OF A STRENGTH SUFFICIENT TO PREVENT TEARING OR
BURSTING UNDER NORMAL CONDITIONS OF USE AND
HANDLING; AND
5)
SEALED TO PREVENT LEAKAGE DURING TRANSPORT.
(Section
56.1(b) (2) (A))
b) Sharps unless treated and rendered unrecognizable
pursuant to 35 Ill. Adm. Code 1422.126, must be
packaged in a container, or a combination of
containers, that is puncture-resistant and meets the
requirements of subsection (a) of this Section.
c) Oversized P1MW must be covered or packaged in a manner
that minimizes contact with transport workers and the
public. Sharps must not be packaged with oversized
P1MW in the same container.
d) If the outside of a container is contaminated by P1MW,
a person shall place the container inside another
container, or clean and disinfect the container in
accordance with 35 Ill. Adm. Code 1420.107 of this
Subtitle. In either case, the container or combination
of containers must meet applicable requirements of
subsections (a) or (.b) of this Section.
e) Once a reusable container has been cleaned and
disinfected in accordance with 35 Ill. Adm. Code
1420.107 of this Subtitle, it can be used for only
waste. If a reusable container is not or cannot be
cleaned and disinfected in accordance with Section
1420.107 of this Subtitle, it must be regulated as P1MW
pursuant to this Subtitle.
f) Residues from cleaning a P1MW container, or discharges
from P1MW packages, are regulated under this Subtitle,
except when discharged directly into a sanitary or
combined sewer in accordance with 35 Ill. Adm. Code:
Subtitle C.
BOARD NOTE: Interested persons should note that
discharges to sewer systems can also be regulated by
units of local government.
SUBPART D: LABELING AND MARKING
Section 1421.130 Scope and Applicability
This Subpart applies to persons who package P1MW for off-site
transportation or who accept packages of P1MW from off—site.
Section 1421.131 Standards and Criteria
G1~3-031E~
—53—
a) The exterior of the outer package must be marked as
follows prior to shipment:
1) The generator shall:
A) Mark on two opposite sides of the outer
package in bettering that is readable at a
minimum distance of five (5) feet:
i) The International Biohazard Symbol as
shown in Illustration A of this Part and
the word “Biohazard”; and
ii) The word “sharps”, if the package
contains sharps.
B) Mark with indelible ink in lettering that is
legible on a water-resistant
label or tag
securely attached to or marked on the outer
package:
i) The generator’s name,
ii) The generator’s address, and
iii) The generator’s phone number (a 24—hour
phone number, if available).
2) The transporter shall mark with indelible ink in
lettering that is legible on a water-resistant
label or tag securely attached to or marked on the
outer package:
A) The transporter’s name,
B) The transporter’s permit number,
C) The transporter’s address,
D) The transporter’s phone number (a 24—hour
phone number, if available), and
E) For each P1MW package, the shipment date when
P1MW initially left the generator’s site; or
for each shipment, a unique identification
number which directly corresponds to the
initial date, of shipment.
b) Except for subsection (c) of this Section, inner
packages must be marked as described in subsection
(a) (1) (A) (1) of this Section.
—54—
c)
If a sharps container is packaged within an outer
container, the inner sharps container must be marked
with indelible ink in lettering that is legible as
follows:
1) The International Biohazard Symbol as shown in
Illustration A of this Part and the word
“biohazard”; and
2) The word “sharps”.
d) Containers which are not the inner or outer containers
are exempt from the labeling requirements in subsection
(a) of this Section. Packages may be placed in a
transparent container provided that all required
markings are legible through the transparent container.
A non—rigid transparent container cannot be used as an
outer container.
e) For oversized P1MW, the following requirements must be
met prior to shipment:
1) The generator shall:
A) Mark on one side of the outer package in
lettering that is readable at a minimum
distance of five (5) feet the International
Biohazard Symbob as shown in Illustration A
of this Part and the word “biohazard”.
B) Mark with indelible ink in lettering that is
legible on a water—resistant label or tag
securely attached to or marked on the outer
package:
i) The generator’s name,
ii) The generator’s address, and
iii) The generator’s phone number (a 24—hour
phone number, if available).
2) The transporter shall mark with indelible ink in
lettering that is legible on a water-resistant
label or tag securely attached to or marked on the
outer package:
A) The transporter’s name,
B) The transporter’s permit number,
C) The transporter’s address,
tii4u u~J
—55—
D)
The transporter’s
phone number (a 24—hour
phone number,
if available), and
E) For each
P1MW package, the shipment date when
P1MW initially left the generator’s site; or
for each shipment, a unique identification
number
which directly corresponds to the
initial
date of shipment.
f)
When P1MW is transported
by more than one transporter,
each transporter
shall mark with indelible
ink in
lettering
that is legible on a water—resistant
label or
tag securely attached to or marked on the outer package
the information listed
in subsection (a) (2) of this
Section. The label, tag or mark must not obscure any
previous information on the package.
SUBPART E: TRANSPORTATION
Section 1421.140 Scope and Applicability
This Subpart applies to persons who transport P1MW and are
required to have a P1MW hauling permit in accordance with 35 Ill.
Adm. Code 1420.105 of this Subtitle.
Section 1421.141 Standards and Criteria
a) P1MW must be transported under conditions to minimize
the effects of putrescence.
b) Packages of P1MW must be transported only in enclosed
compartments of vehicles that are secured against
public access when unattended. This requirement does
not apply to oversized P1MW, which must be handled in a
manner that minimizes contact with transport workers
and the public.
c) Vehicles and associated storage compartments, doors,
piping and valving must be:
1) Cleaned of visible P1MW contamination after each
use; and
2) In good repair when transporting P1MW.
d) P1MW must be transported in a manner that prevents a
breeding place or food source for vectors.
e) During transport, a P1MW package must not be compacted
or subjected to stress that compromises the integrity
of the container.
01
L~.3-Q3
17
—56—
f)
Residues from the cleaning of vehicles contaminated by
P1MW
are regulated under this Subtitle, except
when
discharged directly
into a sanitary or combined sewer
in accordance
with 35 Ill. Adm.
Code Subtitle C.
BOARD NOTE: Interested persons should note that
discharges to sewer systems can also be regulated by
units of local government.
g) Vehicles transporting P1MW must display information in
accordance with the P1MW hauling permit.
h) The transporter shall develop and keep an emergency
response plan in the vehicle. This plan must identify
the names and telephone numbers of State and local
authorities who must be contacted in the event of an
emergency or discharge. In the event of an emergency
or discharge of P1MW, the transporter shall take
immediate action in accordance with the emergency
response plan to protect the health and safety of the
public and the environment. In addition, each vehicle
transporting P1MW must carry all equipment necessary to
provide a response.
i) Vehicles transporting P1MW must not be used for the
hauling of non—waste materials, with the exception of
equipment and supplies intended for the use of waste
management, including scales, bar coding equipment,
printers, stampers, manifests, logs, dollies, load
locks, conveyers, material handling equipment, plastic
containers, corrugated boxes, plastic bags, tape,
sharps containers, drums, labels, signs, stickers,
spill kits, new P1MW containers or P1MW containers that
have been cleaned and disinfected in accordance with 35
Ill. Adm. Code 1420.107 of this Subtitle.
j)
P1MW must not be in transport for more than ten (10)
calendar days.
k) This Subpart does not apply to the United States Postal
Service.
1) COMMENCING
MARCH 31, 1993,
AND ANNUALLY THEREAFTER,
EACH
TRANSPORTER OF P1MW REQUIRED TO HAVE A PERMIT
UNDER SUBSECTION (f) OF
SECTION 56.1 OF THE ACT SHALL
FILE
A REPORT WITH THE AGENCY SPECIFYING THE QUANTITIES
AND DISPOSITION OF P1MW TRANSPORTED DURING THE PREVIOUS
CALENDAR YEAR.
SUCH REPORTS SHALL BE ON FORMS
PRESCRIBED
AND
PROVIDED BY THE AGENCY.
(Section 56.3
of the Act)
01143-0318
—57—
Section 1421.IllustratiOfl
A
01 t~i.3-0319
—58—
TITLE 35:
ENVIRONMENTAL PROTECTION
SUBTITLE
M: BIOLOGICAL MATERIALS
CHAPTER I: POLLUTION CONTROL BOARD
SUBCHAPTER
b: POTENTIALLY INFECTIOUS MEDICAL
WASTES
PART 1422
DESIGN
AND
OPERATION OF FACILITIES
SUBPART A:
GENERAL PROVISIONS
Section
1422.101
1422.105
1422.106
1422.107
Section
1422.110
1422.111
Section
1422. 120
1422. 121
1422. 122
1422.123
1422.124
1422.125
1422.126
1422.127
Section
1422 .APPENDIX
TABLE A
TABLE B
TABLE C
1422 .APPENDIX
Compliance Date
P1MW Permit Application Contents
P1MW Permit Application Certifications
P1MW Permit Application Filing Requirements
SUBPART B:
STORAGE OR TRANSFER OPERATIONS
Scope and Applicability
Design and Operating Standards and
Criteria
SUBPART C:
TREATMENT FACILITIES
Scope and Applicability
Treatment Facility Certification
Design and Operating Standards
Treatment Units
Initial Efficacy Test
Periodic Verification Test(s)
Sharps
Experimental Permits
A Initial Efficacy Test Procedures
Test Microorganisms
Indicator Microorganisms
Challenge Loads
B Correlating Periodic Verification Test
Procedures
AUTHORITY:
Implementing and authorized
by Sections 56.2 and 27
of the Environmental Protection Act (Ill. Rev. Stat. 1991, ch.
111 1/2, pars. 1056.2 and 1027) 415 ILCS 5/56.2 and 27.
SOURCE: Adopted in R91-20, at
Ill. Reg.
_______,
effective
NOTE: Capitalization denotes statutory language.
01
b,3-0320
—59—
SUBPART A: GENERAL
PROVISIONS
Section 1422.101
Compliance Date
Persons subject to this Part shall comply with its requirements
by
,
1993 (effective date).
Section 1422.105
P1MW
Permit Application Contents
An application
for a permit for a P1MW treatment,
storage or
transfer operation must contain the
information specified in this
Section. If the applicant believes that the documentation or
information required pursuant to any subsection of this Section
is not applicable for reasons such as irrelevancy, the
application must include the reasons in support of such belief.
a) Legal description of the site at which the facility is
to be located.
b) Maps and floor plans showing the location of the
facility, the facility boundary and the location of all
units included in the facility.
c) Process flow diagrams or schematic drawings showing the
flow of waste through the facility. The diagrams or
drawings must show, but not be limited to, the
locations of residuals, recycled streams, sample
points, equipment and process monitoring devices.
Equipment must be labeled on the process flow diagram
to correspond to an equipment number.
d) Written description of the facility or facility
operations with supporting documentation describing the
procedures and plans that will be used at the facility
to comply with the requirements of Parts 1420 through
1422 of this Subtitle and any other applicable Parts of
35 Ill. Adm. Code: Chapter 1. Such description must
include, but not be limited to, the following
information:
1) The type of waste management units and the types
and volumes of waste;
2) The overall process to be used for treating or
storing
P1MW
and the anticipated performance of
the process;
3) In detail, the major activities at the facility,
such as transfer, storing, screening, weighing,
processing and treatment (including the number of
units) of P1MW;
01 ~~3-.Q32I
—60—
4)
The operations for initial
facility
startup, daily
startup and scheduled and unscheduled shutdowns;
5)
The days and hours of operation;
6)
The operating parameters for
the treatment units;
7)
The safety and monitoring equipment for the
treatment units;
8) A cleaning and disinfection plan describing the
daily cleanup procedures, including the methods to
disinfect emptied reusable P1MW containers,
transport vehicles, and facility surfaces and
equipment contaminated with P1MW;
9) The methods to control: emissions of odors and
aerosols generated, including all supporting
design and engineering data; dust, noise, litter
and vectors; and handling and storing;
10) The methods to treat, transfer, or dispose of
residual wastes generated from the operation of
the facility;
11) Adequacy of the utilities to operate the facility
and to respond to emergency situations;
12) Numbers and duties of employees directly
responsible for the operation of the site or
facility; and
13) Location and type of security devices to prevent
unauthorized access.
e) A waste screening plan that describes procedures to be
used to identify and prevent the acceptance of
unauthorized wastes.
f) Description of procedures to be used for inspection,
contingency, recordkeeping and closure plans as
required by this Part.
g) For a facility at which the owner or operator is
required to conduct either Initial Efficacy Tests or
Periodic Verification Tests, a written description of
procedures to be used for recordkeeping, classifying
residuals and collecting data for the Document of
Initial Efficacy Demonstration and Correlating Periodic
Verification Demonstration.
Section 1422.106
P1MW Permit Application Certifications
—61—
An application for a permit for P1MW treatment, storage or
transfer operation must contain the certifications specified in
this Section.
a) The permit application must contain a certificate of
ownership of the permit area or a copy of the lease and
its duration. The lease must clearly specify that the
owner authorizes the construction of a P1MW waste
management facility on the leased premises. The owner
or operator shall certify that the Agency will be
notified 30 days prior to any changes in ownership or
conditions in the lease affecting the permit area.
b) All permit applications must be signed by a duly
authorized agent of the operator and the property
owner, must be accompanied by an oath or affidavit
attesting to the agent’s authority to sign the
application and must be notarized. The following per-
sons are considered duly authorized agents of the
operator and the property owner:
1) For corporations, a principal executive officer of
at least the level of vice president;
2) For a sole proprietorship or partnership, a
proprietor or general partner, respectively; and
3) For a municipality, state, federal or other public
agency, by the head of the agency or ranking
elected official.
c) All permit applications must contain the name, address,
and telephone number of the duly authorized agent of
the operator and the property owner to whom all
inquiries and correspondence must be addressed.
d) All designs presented in the application must be
prepared by, or under the supervision of, a
professional engineer. The professional engineer shall
affix the name of the engineer, date of preparation,
registration number, a statement attesting to the
accuracy of the information and design and a
professional seal to all designs.
e) The applicant must state whether the facility is a new
regional pollution control facility, as defined in
Section 3.32 of the Act, which is subject to the site
location suitability approval requirements of Sections
39(c) and 39.2 of the Act. If such approval by a unit
of local government is required, the application must
identify the unit of local government with
jurisdiction. The application must contain any
p~It
r
ç’~F)1)t)
U
I 4
~‘
—62—
approval issued by that unit of local government. If
no approval has been granted, the application must
describe the status of the approval request.
Section 1422.107 P1MW Permit Application Filing Requirements
a) All permit applications must be filed with the Agency
on forms as prescribed by the Agency. Hand delivered
applications must be delivered during the Agency’s
normal business hours to the offices of the Permit
Section. The Agency shall provide a dated, signed
receipt of filing only if the applicant requests. The
date of filing must be that recorded by the Agency,
unless proven otherwise by a dated, signed receipt.
b) The permit application must be accompanied by all
filing fees required pursuant to Section 5(f) of the
Act.
SUBPART B:
STORAGE OR TRANSFER OPERATIONS
Section 1422.110
Scope and Applicability
This Subpart applies to the owner or operator of a
P1MW
storage
site or transfer station,
collectively referred to as a “storage
operation” in this Subpart.
Section 1422.111 Design and Operating Standards and Criteria
a) ANY PERSON WHO STORES P1MW PRIOR
TO TREATMENT OR
DISPOSAL ON-SITE OR TRANSPORT OFF-SITE MUST COMPLY WITH
ALL OF THE FOLLOWING STORAGE REQUIREMENTS:
1) STORE THE P1MW IN A MANNER AND LOCATION THAT
MAINTAINS THE INTEGRITY OF THE PACKAGING AND
PROVIDES PROTECTION FROM WATER, RAIN, AND WIND.
2) MAINTAIN THE P1MW IN A NONPUTRESCENT STATE, USING
REFRIGERATION WHEN NECESSARY.
3) LOCK THE OUTDOOR STORAGE AREAS CONTAINING P1MW TO
PREVENT UNAUTHORIZED ACCESS.
4)
LIMIT ACCESS TO ON-SITE STORAGE AREAS TO
AUTHORIZED EMPLOYEES.
5)
STORE THE
P1MW IN A MANNER
THAT AFFORDS PROTECTION
FROM
ANIMALS
AND DOES NOT PROVIDE
A BREEDING PLACE
OR FOOD SOURCE FOR vectors. (Section
56.1(e) (2) (D) (i)—(v) of the Act)
r
i
—63—
6) P1MW packages must not be compacted or subjected
to stress that compromises the integrity of the
container.
7) Multiple generators in the same building may store
their P1MW packages in a common storage area.
8) Reusable P1MW containers or facility equipment
(e.g., carts, squeegees or shovels) which are
visually contaminated with P114W must be cleaned in
a designated area in accordance with 35 Ill. Adm.
Code 1420.107 of this Subtitle.
9) Residues from cleaning a P1MW contaminated
container, equipment or work surface are regulated
under this Subtitle, except when directly
discharged into a sanitary or combined sewer in
accordance with 35 Ill. Adm. Code: Subtitle C.
BOARD NOTE: Interested persons should note that
discharges to sewer systems can also be regulated
by units of local government.
10) Copies of all P1MW manifests required by 35 Ill.
Adm. Code 1420.105 of this Subtitle must be
retained by and kept at the storage operation for
three (3) years and must be made available at the
storage operation during normal business hours for
inspection and photocopying by the Agency. The
retention period for P1MW manifests is extended
automatically during the course of any unresolved
enforcement action regarding the storage operation
or as requested in writing by the Agency.
11) Upon closure of a storage operation, the owner or
operator shall clean the area, equipment and
structures in accordance with 35 Ill. Adm. Code
1420.107 of this Subtitle.
b) In addition to the requirements listed in subsection
(a) of this Section, storage operations required to
have a permit pursuant to 35 Ill. Adin. Code 1420.105 of
this Subtitle must also comply with the following
requirements that the Agency shall review during the
permitting process:
1) Storage operations shall weigh in pounds the
amount of P1MW received, unless previously weighed
by the transporter. P1MW must be weighed with a
device for which certification has been obtained
under the Weights and Measures Act (Ill. Rev.
01 L~.3-0325
—64—
Stat. 1991, ch. 147, pars. 101 et seq.)
225 ILCS
470.
2) P1MW packages must be stored in designated areas
so as not to contaminate other waste or materials.
3) Cardboard packages must be stored in an enclosed
area at an elevation above that of the floor.
4) P1MW must be stored on a surface that allows
drainage and collection of liquids and that
minimizes exposure to workers and the public.
5)
Adequate aisle space, as specified
in the permit,
must be maintained between packages to allow
inspection
of at least one (1) side of each
package.
Packages must be stacked so that labels
are readable.
A vehicle containing P1MW is exempt
from the above aisle space requirement:
A)
When loading or unloading a vehicle; or
B)
When a fully—loaded vehicle is on a site.
Either exemption, or both exemptions, must not
exceed five (5) calendar days.
6)
Material handling equipment must be designed so as
to maintain the integrity
of the package.
7)
Signs identifying
the storage operation must be
prominently displayed at the points of access to
the secured storage area.
Signs must be marked in
lettering
that is readable at a minimum distance
of five (5) feet.
At a minimum, the signs must
display the International
Biohazard Symbol as
shown in 35 Ill.
Adni.
Code 1421.Illustration
A and
the word “biohazard”.
8)
Personnel training must be provided to all staff
prior to the handling of P1MW. Annual personnel
training must include, at a minimum, a thorough
explanation
of the operating procedures to be
taken during normal and emergency situations.
The
owner or operator shall keep records verifying
training
of personnel.
9)
Storage operations must have a written contingency
plan and the applicable
sections must be
implemented in the event of a discharge or
personal injury.
The contingency plan must
describe the actions that personnel shall take in
‘~
r”~’~
Ut ~
—65—
response to emergency situations such as, but not
limited to, personal injury, discharges of P1MW,
rupture of plastic bags and equipment failure.
This contingency plan must, at a minimum, include
a list of all emergency equipment at the storage
operation, an up—to—date list of names, addresses
and phone numbers (office and home) of all persons
qualified to act as emergency coordinator,
procedures for cleanup, protection of personnel,
disposal of spill residue, repackaging of P1MW and
alternate arrangements for P1MW storage and
transfer. A copy of the contingency plan must be
maintained at the storage operation. Emergency
phone numbers and a brief description of the
emergency procedures must be posted at the storage
operation.
10) The owner or operator shall keep a written
operating record at the storage operation. At a
minimum, the following information must
be
recorded and maintained in the operating record:
A)
Quantities and disposition of
P1MW stored
or
transferred;
B) Date and time
the P1MW arrived at the
permitted storage operation
site;
C) Date and
time the P1MW left the storage
operation;
D)
Waste stream permit number
(authorization
number), if applicable, issued by the Agency;
E) Generator name(s), location(s) and if
applicable, the generator
identification
number(s) issued by the Agency for each P1MW
load received at the storage operation;
F) Temperature(s) the P1MW load was maintained
at the storage operation;
G) Destination of packages, which must include
at a minimum the name of the receiving
facility, the location of the receiving
facility, the
identification number of the
receiving facility issued by the Agency (if
applicable) and the disposition (i.e.,
storage, transfer, treatment or disposal);
and
01 I~3-0327
—66—
H) In a separate log, the
date, time, nature and
extent of all discharges and personal
injuries and the date,
time, nature and
result of any response(s) taken.
11) The records required by subsections (b) (8) and
(10) of
this
Section must be retained by and kept
at the storage operation and
must be made
available at the storage operation during normal
business hours for inspection and photocopying by
the Agency. These records must be kept until
closure of the storage operation. The retention
period is extended automatically during the course
of any unresolved enforcement action regarding the
storage operation or as requested in writing by
the Agency.
12) Unless otherwise authorized by the Agency
in the
permit, P1MW
must not be stored for more than:
A) Seventy-two (72) hours at the storage
operation unless the surface temperature of
the package is maintained at or below 45
degrees Fahrenheit, and
B) Thirty (30) days
at the storage operation
regardless of temperature.
13) At least sixty (60) days prior to closing a
storage operation, the owner or operator shall
notify the Agency of the planned closure. Within
ninety (90) days after the date the final load of
P1MW is received at the storage operation,
the
owner or operator shall certify to the Agency that
final closure has been completed in accordance
with the permit, the
Act and all applicable
regulations promulgated
thereunder.
SUBPART C:
TREATMENT FACILITIES
Section 1422.120
Scope and Applicability
This Subpart applies to the owner or operator of a facility in
Illinois that is designed to treat P1MW to eliminate its
infectious potential. This Subpart also applies to owners or
operators of treatment facilities where the treated P1MW
residual
is disposed of in Illinois. For purposes of this Part, a
facility or operation that is designed to treat P1MW to eliminate
its infectious potential is referred
to as a “treatment
facility”.
Section 1422.121
Treatment Facility Certification
U~4JUJ
—67—
No person shall cause or allow the disposal of any P1MW where the
infectious potential has been eliminated by treatment unless the
treatment facility
certifies to the transporter, if other than
the generator,
and certifies to the landfill operator or
receiving facility operator that the
P1MW has been treated in
accordance with
this Part, and,
if applicable, with
all terms and
conditions specified
in its operating permit. Data to verify the
efficacy of the treatment unit must be made available to the
receiving facility upon request of the receiving facility. No
person shall falsely certify that
P1MW
has been treated
in
accordance with this Part.
Section 1422.122
Design and Operating Standards
a) Treatment of P1MW must be conducted in a manner that:
1) ELIMINATES THE INFECTIOUS POTENTIAL OF THE
WASTE. A treatment process eliminates the
infectious potential of P1MW if the owner or
operator of a treatment unit demonstrates
that an Initial Efficacy Test and Periodic
Verification Test have been completed
suc-
cessfully.
A) Successful completion of an Initial Efficacy
Test must be demonstrated by a 6-log kill of
test
microorganisms. For a thermal unit that
maintains the
integrity of the container, a
6—log kill of indicator microorganism spores
may be used as an alternative test. These
demonstrations must be conducted in
accordance with Section 1422.124.
B) Successful completion of a Periodic
Verification Test must be demonstrated, in
accordance with Section 1422.125, by:
i) a 6-log kill of test microorganisms or
indicator microorganism spores as
provided in subsection (a) (1) (A) above;
or
ii)
a minimum 3-log kill of indicator
microorganism spores that has been
correlated with a 6-log kill of test
microorganisms; or
iii) an alternate method submitted to and
approved in writing by the Agency.
2) PREVENTS THE COMPACTION AND RUPTURE OF CONTAINERS
DURING HANDLING OPERATIONS, except when compaction
0
—68—
or rupture is an integral part of the treatment
process and the treatment process is conducted
without discharge of P1MW
to the environment;
3)
DISPOSES OF TREATMENT RESIDUALS
IN ACCORDANCE WITH
THIS ACT AND REGULATIONS ADOPTED THEREUNDER;
4)
PROVIDES FOR QUALITY ASSURANCE PROGRAMS that must
include, at a minimum, a written plan that:
A) Designates responsibility to personnel;
B) Describes operating parameters that must be
monitored to insure effectiveness of the
treatment process;
C) Identifies monitoring devices;
D) Insures monitoring devices are operating
properly;
E) Establishes appropriate ranges for all
operating parameters;
F) Identifies the person(s) who shall collect
and organize data for inclusion in the
operating record;
G)
Identifies the person(s)
who shall evaluate
any discrepancies
or problems;
H)
Identifies the person(s) who
shall propose
actions to correct any problems identified;
and
I) Identifies the person(s) who shall assess
actions taken and document improvement;
5)
PROVIDES FOR PERIODIC TESTING USING BIOLOGICAL
TESTING, WHERE APPROPRIATE, THAT DEMONSTRATE
PROPER TREATMENT OF THE WASTE;
6)
PROVIDES FOR ASSURANCES THAT CLEARLY DEMONSTRATE
THAT POTENTIALLY INFECTIOUS MEDICAL WASTE
HAS
BEEN
PROPERLY TREATED; and
7) IS IN COMPLIANCE WITH ALL FEDERAL AND STATE LAWS
AND REGULATIONS PERTAINING TO ENVIRONMENTAL
PROTECTION. (Section 56.2(a) (1)—(7) of the Act)
b) In addition to the
requirements in subsection (a) of
this Section:
Oti~3-033O
—69—
1) Residues from cleaning a
P1MW contaminated
container, equipment or work surface are regulated
under this Subtitle, except
when directly
discharged into
a sanitary or combined sewer in
accordance with
35 Ill. Adin. Code: Subtitle C.
BOARD NOTE: Interested persons should note that
discharges to sewer systems can also be regulated
by units of local government.
2) Ash resulting from the incineration of P1MW
is an
industrial process waste, as defined in Section
3.17 of the Act, and must be managed as a special
waste in accordance with 35
Ill.
Adm. Code 807 and
809.
3) Copies of P1MW manifests required by 35 Ill. Adm.
Code
1420.105 of this Subtitle must be retained by
and kept at the
treatment facility for three (3)
years and must be made available at the treatment
facility during normal business hours for
inspection and photocopying by the Agency. The
retention period for P1MW manifests is extended
automatically
during the course of any unresolved
enforcement action regarding the treatment
facility or as requested in writing by the Agency.
4) COMMENCING MARCH 31, 1993, AND
ANNUALLY
THEREAFTER,
EACH
TREATMENT FACILITY FOR WHICH A
PERMIT IS REQUIRED pursuant
to
35 Ill. Adni. Code
1420.105 of this Subtitle and EACH FACILITY NOT
REQUIRED TO HAVE
A PERMIT pursuant to Section
1420.105 of this Subtitle THAT TREATS MORE THAN
50
POUNDS PER MONTH OF POTENTIALLY INFECTIOUS MEDICAL
WASTE
SHALL
FILE A REPORT WITH THE AGENCY
SPECIFYING THE QUANTITIES AND DISPOSITION OF
POTENTIALLY INFECTIOUS MEDICAL WASTE TREATED
DURING THE PREVIOUS CALENDAR YEAR.
SUCH REPORTS
SHALL BE ON FORMS PRESCRIBED AND PROVIDED BY THE
AGENCY. (Section 56.3 of the Act)
5) Upon closure of a treatment facility, the owner or
operator shall clean the area, equipment and
structures in accordance
with 35
Ill.
Adm.
Code
1420.107 of this Subtitle.
C) In addition to the requirements listed in subsections
(a) and (b) of this Section, owners or operators of
treatment facilities required to have a permit pursuant
to 35 Ill. Adin. Code 1420.105 of this Subtitle shall
also comply with the following requirements that the
Agency shall review during the permitting process:
01 ~3-0331
—70—
1) Amounts of P1MW received must be weighed in pounds
with a device for which certification has been
obtained under the Weights and Measures Act (Ill.
Rev. Stat.
1991, ch. 147, pars. 101 et seq.) 225
ILCS 470.
2) Signs identifying that the facility treats P1MW
must be prominently displayed at the points of
access to the treatment area. Signs must be
marked in lettering that is readable at a minimum
distance of five (5) feet. At a minimum, the
signs must display the International Biohazard
Symbol as shown in 35 Ill. Adin. Code
l421.Illustration
A and the word “biohazard”.
3) Personnel training
must be provided to all staff
prior to the handling of P1MW.
Annual personnel
training must include, at a minimum, a thorough
explanation of the operating procedures to be
taken during normal and emergency situations. The
owner or operator shall keep records verifying
training of personnel.
4)
Treatment
facilities must have a written
contingency plan and the applicable sections must
be implemented in. the event of a discharge,
equipment failure or personal injury. The
contingency plan must describe the actions that
personnel shall take in response to emergency
situations~such as, but not limited to, personal
injury, discharges of P1MW and equipment failure.
This contingency plan must, at a minimum, include
a list of all emergency equipment at the treatment
facility, an up-to—date list of names, addresses
and phone numbers (office and home) of all persons
qualified to act as emergency coordinator,
procedures for cleanup, protection of personnel,
disposal of spill residue and alternative
arrangements for P1MW treatment. A copy of the
contingency plan must be maintained at the
treatment facility.
Emergency phone numbers and a
brief description of the emergency procedures must
be posted at the treatment facility.
5) The owner or operator shall keep a written
operating record at the treatment facility. At a
minimum, the following information must be
recorded and maintained in the operating record:
A) Quantities and disposition of P1MW treated;
01 li,3-0332
—71—
B) Date and time the P1MW arrived at the
permitted
P1MW
site;
C) Date and time the
P1MW was treated;
D) The operating parameters of the treatment
unit (e.g., temperature, pressure, residence
time, chemical concentration, irradiation
dose);
E) Date and time the P1MW left the treatment
facility;
F) Generator name(s), location(s) and, if
applicable, the generator identification
number(s) issued by the Agency for each P1MW
load received at the’ treatment facility;
G) The destination of the
treated waste which
must include, at a minimum, the name
of the
receiving facility, the location
of the
receiving facility, the identification number
of the receiving facility issued by the
Agency (if applicable) and the disposition;
and
H)
In a separate log, the date, time, nature and
extent of all discharges and personal
injuries and the date, time, nature and
result of any response(s) taken.
6) The records required by subsections (c) (3) and
(C) (5) of this Section must be retained by and
kept at the treatment facility and must be made
available at the treatment facility during normal
business hours for inspection and photocopying by
the Agency. These records must be kept until
closure of the treatment facility. The retention
period is extended automatically during the course
of any unresolved enforcement action regarding the
treatment facility or as requested in writing by
the Agency.
7) At least sixty (60) days prior to closing a
treatment facility, the owner or operator shall
notify the Agency of the planned closure. Within
ninety (90) days after the date the final load of
P1MW is received at the treatment facility, the
owner or operator shall certify to the Agency that
final closure has been completed in accordance
with the permit, the Act, and all applicable
regulations promulgated thereunder.
(‘~ñ
U14~U~)
—72—
Section 1422.123
Treatment Units
a)
A treatment unit must be:
1) Designed and operated to eliminate the infectious
potential of P1MW as demonstrated by the Initial
Efficacy Test and Periodic Verification Tests,
pursuant to Sections 1422.124 and 1422.125 of this
Part;
2) Operated according to the manufacturer’s
instructions,
if it is a commercially available
unit;
3) Operated under the same conditions that have been
used to demonstrate that the infectious potential
was eliminated in accordance with this Part;
4)
Operated with a
P1MW feed rate not to exceed that
which was used to demonstrate that the infectious
potential was eliminated; and
5) Designed and operated to limit the emission of
microorganisms into the air.
b) A treatment unit
may be used by the owner or operator
of
a treatment facility not required to have a permit
pursuant to 35 Ill. Adin. Code 1420.105 of this
Subtitle, if the requirements of subsection (b) (1) or
(2) below are met.
1)
The treatment unit meets the standards of
subsections (a) (1)—(5)
of this Section, and:
A) The treatment
unit utilizes a thermal,
chemical or irradiation treatment, as defined
in 35 Ill. Adm. Code 1420.102 of this
Subtitle; or
B) The owner or operator maintains a copy of the
Initial Efficacy Test results for the
treatment unit. In addition, the owner or
operator shall conduct Periodic Verification
Tests in accordance with the manufacturer’s
instructions and Section 1422.125.
Test
results
shall be retained and made available
for inspection in accordance with Section
1422.125(d) and (g); and
C) The owner or operator retains any
notification from the manufacturer of the
0
i~
3- 0 33
L~
—73—
permitted commercially available treatment
unit of a permit modification.
2) The Board has granted the owner’s or operator’s
petition for an adjusted standard pursuant to 35
Ill. Adm. Code 106.Subpart G or a site-specific
rulemaking pursuant to 35 Iii. Adm. Code 102. The
petition must include a demonstration that the
treatment unit meets the standards of subsection
(a) (1)-(5) of this Section.
c) For an autoclave, incinerator or ethylene oxide unit
installed or operated prior to the effective date of
these regulations, an Initial Efficacy Test is not
required.
The first Periodic Verification Test must be
performed within
three
(3) months of the
effective date
of these
regulations to demonstrate that the infectious
potential has
been eliminated.
d) For treatment facilities
required to have a permit
pursuant to 35 Ill. Adm. Code 1420.105 of this
Subtitle, the permit application must include, at a
minimum, the following information regarding the
treatment unit:
1) An operating plan that includes a description of
the treatment facility’s operating procedures and
parameters; and
2) Test data and supporting documentation
demonstrating that the infectious potential has
been eliminated from either similar existing
P114W
treatment units or pilot
projects.
e) The treated
P1MW is managed in accordance with this
Subtitle and 35 Ill.
Adin. Code: Subtitle G.
Section 1422.124
Initial Efficacy Test
a) The manufacturer, owner or operator of a treatment unit
shall conduct an Initial Efficacy Test, pursuant to
Appendix A of this Part, for each model prior to its
operation. If significant mechanical changes are made
to a treatment unit, the Initial Efficacy Test must be
repeated. Treatment units are considered to be the
same model if they:
1) Are manufactured by the same company;
2) Have the same capacity; and
3) Have no significant mechanical changes.
U4
—74—
b) The Initial Efficacy Test must
be conducted by the use
of Options 1, 2 or
3 of Appendix A of this Part, and
the challenge
loads as described in Table C of Appendix
A of this Part.
If any of the challenge loads fails
the Initial Efficacy Test, the operating conditions
must be revised and the Initial Efficacy Test must be
repeated for all challenge loads. The Initial Efficacy
Test must also meet the requirements of this Section.
1) Option 1 must be used for a treatment unit that
does
not maintain the integrity of the container
of test microorganisms (e.g., grinding followed
by
chemical disinfection).
This option is a two
phase test.
A)
The
first phase is to determine the dilution
of each test, microorganism from the operation
of the treatment unit for each challenge
load. The log of the number of viable test
microorganisms in the processed residue must
be greater than or equal to six (6).
B) The second phase is to determine the
effectiveness of the treatment unit. The log
kill
(L) for each test microorganism after
treatment must be greater than or equal to
six (6)
2) Option 2 must be used for a treatment unit that
maintains the integrity of the container of test
microorganisms (e.g., autoclaving). The log kill
(L) for each test microorganism after treatment
must be greater than or equal to six (6).
3) Option 3 can only be used for a thermal treatment
unit that maintains the
integrity of the container
of indicator microorganism spores (e.g.,
autoclaving, incinerating). The log kill (L) of
indicator ‘microorganism spores after treatment
must be greater than or equal to six (6).
c)
Composition of Challenge
Loads
1) For treatment units
designed to treat all types of
P1MW, all three (3) types of challenge loads must
be used in conducting the Initial Efficacy Test.
The three (3) types of challenge loads represent
P1MW with a high
moisture content, low moisture
content and high organic content. The quantity of
each challenge load must equal 100 of the maximum
capacity of the treatment unit. Each challenge
load must include, at a minimum, 5 of each of the
—75—
following categories: blood/broth cultures,
fibers, metals, sharps, plastics, pathological
waste, glass, non-woven fibers and bottles of
liquids. Table C of Appendix A of this Part
contains the moisture
and organic content
requirements that must be met in each type of
challenge load.
2) For treatment units designed to treat only select
categories of P1MW (e.g., a sharps treatment
unit), a modification in the composition of the
challenge load(s) may be used if approved by the
Agency in writing.
d) The Initial Efficacy Test must be conducted under the
same operating conditions under which the treatment
unit operates on a day—to—day basis. The feed rate for
the treatment unit must remain constant throughout the
Initial Efficacy Test. This feed rate must never be
exceeded during the operation of the treatment unit.
e) The Initial Efficacy Test must be performed so that:
1) Each container
of test microorganisms and/or
indicator microorganism spores
is placed in the
load to
simulate the worse case scenario (i.e.,
that part of the load that is the most difficult
to treat). For example, the worst case scenario
for an autoclave would be to place the container
of test microorganisms and/or indicator
microorganism spores within a sharps container
that must in turn be deposited in a plastic
biohazard bag that is then located centrally
within each of the challenge loads.
2) Test microorganisms and/or indicator
microorganisms must be cultured and enumerated in
accordance with instructions provided
by the
supplier of the microorganisms and Standard
Methods for the Examination of Water and
Wastewater, incorporated by reference at 35 Ill.
Adm. Code 1420.103.
f) A Document of Initial Efficacy Demonstration must be
retained at the treatment facility, and made available
at the treatment facility during normal business hours
for inspection and photocopying by the Agency. The
Document of Initial Efficacy Demonstration must
include, at a minimum:
1) A detailed description of the test procedures
used, including all test data generated,
with
01
~3-0337
—76—
descriptions of data handling, and a presentation
and interpretation of final test results;
2) A detailed description and verification of the
operating parameters (e.g., temperatures,
pressures, retention times, chemical
concentrations, irradiation doses and feed rates);
3) A description of quality assurance/quality control
procedures and practices for the culture, storage
and preparation of test and/or indicator
microorganisms (including, but not limited to,
organism history, source, stock culture
maintenance and enumeration procedures). The
purity of the test microorganisms and/or indicator
microorganism spores must be certified by a
commercial or clinical laboratory;
4) A description of microorganism preparation and
packaging, challenge load weight and composition,
unit testing scheme (numbers
of test rows) and
sampling strategy (e.g., number and weight of
solid and/or liquid samples);
5) A description and demonstration of microorganism
recovery including sample processing, incubation
and effective neutralization, and absence of toxic
compounds due to neutralization (as applicable);
6) Appendices containing raw data and assumptions in
tabular form;
7) The name(s), date, signature(s) and title(s) of
person(s) conducting the Initial Efficacy Test,
and their qualifications; and
8) A list of references used to evaluate the data and
obtain the final conclusion.
Section 1422.125
Periodic Verification Test(s)
a) The effectiveness of the treatment unit is verified by
the Periodic Verification Test(s), which must be
conducted in accordance with this Section. The
manufacturer, owner or operator of a treatment unit
must perform Periodic Verification Test(s) that satisfy
at least one (1) of the following:
1) Passing the Initial Efficacy Test by using Options
1, 2, or 3 of Appendix A of this Part (whichever
is applicable).
The three challenge loads
01 ~~3-0338
—77—
described in Appendix A, Table C, do not need to
be used. The test microorganisms or indicator
microorganisms must be placed in a representative
load in accordance with Section 1422.124(e) (1)
of
this Part. For example, an autoclave may use
Option 3 (e.g., demonstrate at a minimum the
destruction of one million (1,000,000) Bacillus
stearothermophilus spores) to meet the Periodic
Verification
Tests(s) requirement. In the case of
an
incinerator, a stainless steel pipe
with
threaded ends and removable caps lined with a
ceramic
insulation
may be used to contain a glass
culture vial with Bacillus subtilis spore
strips.
The pipe
with the spore strips may be placed in a
load of P1MW for the Periodic Verification Test.
After the treatment,
the pipe with the spore
strips may be
recovered and the spores may be
cultured
to assess whether, at a minimum, one
million spores have been destroyed to meet the
Periodic Verification Test(s) requirement.
2) Correlating the log kill (L) of the test
microorganisms in the Initial Efficacy Test to an
equivalent log kill (T) of the indicator
microorganism spores in accordance with Appendix B
of this Part. The equivalent log kill (T) of the
indicator microorganism spores must be used for
all subsequent Periodic Verification Tests. The
correlation must be done with the three (3)
challenge loads identified in Table C of Appendix
A of this Part. (See subsection (b) of this
Section for further requirements);
or
3) Submitting and obtaining written approval by the
Agency for a procedure that is equivalent to
subsection (a) (2) of this Section. Examples of
alternatives include, but are not limited to, use
of another indicator microorganism or measurement
of disinfectant concentrations in the treated
residue. For incinerators only, an example of an
alternative
is
visually inspecting the ash from
each load of treated
P1MW
to insure that all
P1MW
within the load
is completely combusted. The
approval of an alternative by the Agency may
require more frequent testing and/or monitoring of
the treatment unit.
b) For the Correlating Periodic Verification Test, which
provides the correlation of log kill (L) of the test
microorganisms with the equivalent log kill (T) of the
indicator microorganisms, the following procedures
apply:
01
L~3-lj339
—78—
1) At a minimum, an initial population of one million
(1,000,000) indicator microorganism spores per
gram of waste solids in each challenge load must
be used;
2)
The fraction of surviving indicator microorganisms
that correlates to a log kill (L) of six (6) for
each test microorganism must be used in future
Periodic Verification Test(s).
(For example, if a
log kill (L) of four (4) for the indicator
microorganism spores per gram of waste solids is
achieved during this demonstration, then a
population of ten thousand (10,000) of the
indicator microorganism must be used in all future
Periodic Verification Test(s)). For future
Periodic Verification Tests, the three challenge
loads described in Appendix A, Table C, do not
need to be used.
The test microorganisms or
indicator microorganism spores must be placed in a
representative
load in accordance with Section
1422.124(e) (1) of this Part;
3)
An equivalent log kill (T) of three (3) for the
indicator microorganism spores must be the minimum
threshold death rate to insure that all test
microorganisms are destroyed;
4) Test microorganisms and/or indicator
microorganisms must be cultured and enumerated in
accordance with instructions provided by the
supplier of the microorganisms and Standard
Methods for the Examination of Water and
Wastewater, incorporated by reference at 35 Ill.
Athu.
Code 1420.103.; and
5)
The Periodic Verification
Test and the Initial
Efficacy Test may be run concurrently to verify
the correlation.
c)
If a load of
P1MW
fails a Periodic Verification
Test(s), the Periodic Verification Test(s) must be
repeated.
The operator shall implement the quality
assurance program (in Section 1422.122 (a) (4) of this
Part) and contact the
manufacturer,
if applicable, to
identify and correct the problem(s) until the unit can
eliminate the infectious potential of the
P1MW.
If the
operating parameters are altered, another Initial
Efficacy Test must be performed to demonstrate the
effectiveness of the unit and, if applicable, another
Periodic
Verification Test correlation, pursuant to
subsection (a) of this Section, must also be repeated.
Loads of
P1MW that were first processed prior to
—79—
receiving results showing a failure of the Periodic
Verification Tests are considered treated.
A second
Periodic Verification Test must be run immediately
after the first Periodic Verification Test indicates a
failure.
The second Periodic Verification Test is to
determine whether or not the treatment unit is
eliminating the infectious potential of the waste.
After the second Periodic Verification Test shows a
failure of the treatment unit, the processed waste is
considered
P1MW
and must be managed in accordance with
this Subtitle.
d) Results of the Periodic Verification Test(s) must be
received, verified and made available for inspection by
the Agency within two weeks of when the test was
conducted.
When a Periodic Verification Test is used
to confirm the failure of a treatment unit, the results
of the Periodic
Verification Test(s) must be received,
verified and made available for inspection by the
Agency within one week of when the test was conducted.
Results of Periodic Verification Tests must be made
available in accordance with the requirements of
subsection (g), below.
e)
Periodic Verification Test(s) must be conducted
monthly, or more frequently if required by the permit
or recommended by the manufacturer.
f)
A Document of Correlating Periodic Verification
Demonstration must be prepared by and retained at the
treatment facility,
and must be available at the
treatment facility during normal business hours for
inspection and photocopying by the Agency.
The
Document of
Periodic Verification Demonstration must
include, at a minimum:
1)
A detailed description of the test procedures used
and documentation showing the correlation between
the log kill (L) of the test microorganisms and
the equivalent kill (T) of the indicator
microorganism spores.
An evaluation of the test
results must include:
All test data generated,
with description of data handling, and a
presentation and interpretation
of final test
results;
2)
A detailed description of the operating parameters
(e.g., temperatures, pressures, retention times,
chemical concentrations,
irradiation dose and feed
rates);
01~3-O3L~I
—80—
3) A description of quality assurance/quality control
procedures and practices for the culture, storage
and preparation of test and/or indicator
microorganisms (including, but not limited to,
organism history, source, stock culture
maintenance and enumeration procedures).
The
purity of the test microorganisms and/or indicator
microorganism spores must be certified by a
commercial or clinical laboratory;
4)
A description of microorganism preparation and
packaging, challenge load weight and composition,
unit testing scheme (numbers of test rows) and
sampling strategy (e.g., number and weight of
solid and/or liquid samples);
5) A description and demonstration of
microorganism
recovery including sample processing, incubation
and effective neutralization,
and absence of toxic
compounds due to neutralization;
6) Appendices containing raw data and assumptions in
tabular form;
7)
The name(s), date, signature(s)
and title(s)
of
person(s) conducting the Initial Efficacy Test,
and their qualifications; and
8) A list of references used to evaluate the data and
obtain the final conclusion.
g) Records of Periodic Verification Test(s) must be
prepared by and retained at the treatment facility, and
made available at the treatment facility during normal
business hours for inspection and photocopying by the
Agency. These records must include, at a minimum:
1)
The dates the Periodic Verification Test(s) were
performed;
2) Operating parameters (e.g., temperatures,
pressures, retention times, chemical
concentrations, irradiation dose and feed rates);
3) Test protocols;
4) Evaluation of test results; and
5)
The name(s), dates, signature(s)
and title(s)
of
person(s) conducting the Periodic Verification
Test(s).
01
~~3-Q3~~2
—81-
h) Periodic Verification Test(s) must be conducted under
the same operating conditions under which the treatment
unit operates on a day—to—day basis. The feed rate for
the treatment unit is the maximum feed rate at which
the unit operates on a day—to—day basis.
The feed rate
must remain constant throughout the Periodic
Verification Test(s). This feed rate must never be
exceeded during the operation of the treatment unit.
Section 1422.126 Sharps
Sharps may be disposed of in a landfill only if they have been
treated to eliminate the infectious potential and:
a) Have been rendered unrecognizable and therefore are no
longer P1MW; or
b)
Have been:
1) Packaged, marked and labeled in accordance with
Part 1421, Subparts C and D;
2) Delivered by a transporter with a P1MW hauling
permit as required by 35 Ill. Adm. Code 1420.105
of this Subtitle, unless specifically exempted;
and
3) Accompanied by a P174W manifest as required by 35
Ill. Adm. Code 1420.105 of this Subtitle, unless
specifically exempted.
Section 1422.127
Experimental Permits
a) The Agency may issue Experimental Permits for processes
or techniques that do not satisfy the standards set
forth in this Subpart if the applicant can provide
proof that the process or technique has a reasonable
chance for success and that the environmental hazards
are minimal. A description of the type of residuals
anticipated and how they will be managed and disposed
of must be included.
b) A valid Experimental Permit constitutes a prima facie
defense to any action brought against the permit holder
for a violation of the Act or regulations promulgated
thereunder, but only to the extent that such action is
based upon the failure of the process or technique.
c) All Experimental Permits have a duration not to exceed
two (2) years. These permits can only be renewed once.
Original experimental permits and renewals granted to
any one person cannot exceed a total of four (4) years.
0
~.3-Q3L~.3
—82—
d) Application for renewal of an experimental permit must
be submitted to the Agency at least ninety (90) days
prior to the expiration of the existing permit. To the
extent the information to be supplied for renewal is
identical with that contained in the prior permit
application, the applicant shall so note on the renewal
application, and the Agency shall not require the
resubmittal of data and information previously supplied
to it.
e) A report must be submitted at the end of the
experimental permit period, or as required by the
Agency, which includes, at a minimum, the following:
1) A summary of operating data, including results of
the Initial Efficacy Test(s) or Periodic
Verification Test(s);
2) A discussion of how the equipment performed;
3) A discussion of how residuals were managed; and
4) A demonstration that the infectious potential has
been eliminated.
Section 1422.APPENDIX A INITIAL EFFICACY TEST PROCEDURES
All
P1MW
treatment units must demonstrate that the infectious
potential has been eliminated by using an Initial Efficacy Test
in accordance with this Appendix.
This Option 1 is for a treatment unit that compromises the
integrity of the container of test microorganisms (e.g., grinding
followed by chemical disinfection).
The purpose of this Phase 1 is to determine the dilution of each
test microorganism from the treatment unit for each challenge
load (Types A through C) identified in Table C of this Appendix.
a) Prepare and sterilize by autoclaving, two (2) challenge
loads of Type A as identified in Table C of this
Appendix. Reserve one (1) challenge load for Phase 2.
b) Each test microorganism must be processed in separate
runs through the treatment unit. Prior to each run,
the number of viable test microorganisms in each
container must be determined in accordance with
applicable manufacturer’s recommendations, and Standard
Methods for the Examination of Water and Wastewater,
incorporated by reference at 35 Ill. Adm. Code
1420.103.
01 ~3-O3~L~
—83—
c) Processing of the P1MW must occur within thirty (30)
minutes after introducing the container of test
microorganisms into the treatment unit.
d) The container of test microorganisms and challenge
loads must be processed together without the physical
and/or chemical agents designed to kill the test
microorganisms. For example, in treatment units that
use chemical disinfectant(s), an equal volume of liquid
(e.g., sterile saline solution (0.9, volume/volume),
phosphate buffer solution, or tapwater) must be
substituted in place of the chemical disinfectant(s).
e) A minimum of five (5) representative grab samples must
be taken from the processed residue of each challenge
load in accordance with Test Methods for Evaluating
Solid Waste, Physical/Chemical Methods (SW-846),
incorporated by reference at 35 Ill. Adm. Code
1420.103. The number of viable test microorganisms in
each grab sample must be determined in accordance with
applicable manufacturer’s recommendations, and Standard
Methods for the Examination of Water and Wastewater,
incorporated by reference at 35 Ill. Adm. Code
1420.103.
f) Calculate the effect of dilution for the treatment unit
as follows:
SA
=
Log N0A
-
Log N1A; where Log N1A ? 6
where: SA is the log of the number of viable test
microorganisms (CFU/gram of waste solids and
PFU/gram of waste solids) that were not
recovered after processing challenge load
Type A.
N0A is the number of viable test
microorganisms (CFU/gram of waste solids and
PFU/gram of waste solids) introduced into the
treatment unit for challenge load Type A.
N1A is the number of viable test
microorganisms (CFU/gram of waste solids and
PFU/gram of waste solids) remaining in the
processed residue for challenge load Type A.
If Log N1A is less than 6, then the number of viable
test microorganisms introduced into the treatment unit
must be increased and steps (a) through (f) in Phase 1
must be repeated until Log N1A is ? 6. N0A is the
inoculum size for challenge load Type A in Phase 2
below.
01
~3-U3L~.5
—84—
g) Repeat steps (a) through (f) in Phase 1 for challenge
loads of P1MW for Types B and C identified in Table C
of this Appendix to determine the effect of dilution
(SB and SC, respectively).
The purpose of this Phase 2 is to determine the log kill of each
test microorganism in each challenge load (Types A through C)
identified in Table C of this Appendix.
a) Using the inoculum size (NoA) determined in Phase 1
above, repeat Phase 1 steps (a) through (e) under the
same operating parameters, except that the physical
and/or chemical agents designed to kill the test
microorganisms must be used.
b) Calculate the effectiveness of the treatment unit by
subtracting the log of viable cells after treatment
from the log of viable cells introduced into the
treatment unit as the inoculum, as follows:
LA=LogNoA-SA-L0gN2A?
6
where: LA is the log kill of the test microorganisms
(CFU/gram of waste solids and PFU/gram of
waste solids) after treatment in the
challenge load Type A.
N0A is the number of viable test
microorganisms (CFU/gram of waste solids and
PFU/gram of waste solids) introduced into the
treatment unit as the inoculum for challenge
load Type A as determined in Phase 1 above.
SA is the log of the number of viable test
microorganisms (CFU/gram of waste solids and
PFU/gram of waste solids) that were not
recovered after processing the challenge load
Type A in Phase 1 above.
N2A is the number of viable test
microorganisms (CFU/gram of waste solids and
PFU/gram of waste solids) remaining in the
treated residue for challenge load Type A.
c) Repeat steps (a) through (b) in Phase 2 for challenge
loads Types B and C identified in Table C of this
Appendix to determine the effectiveness of the
treatment unit (LB and LC, respectively).
This Option 2 is for a treatment unit that maintains the
integrity of the container of test microorganisms (e.g.,
autoclaves).
01
i~j-uj4
—85—
a) One microbiological indicator assay containing one of
the test microorganisms at numbers greater than one
million (1,000,000) must be placed in a sealed
container that remains intact during treatment. The
inside diameter of the container must be no larger than
required to contain the assay vial(s). The vial(s)
must only contain the test microorganisms.
b) The container of test microorganisms must be placed
within a Type A challenge load as identified in Table C
of this Appendix.
c) Calculate the effectiveness of the treatment unit by
subtracting the log of viable cells after treatment
from the log of viable cells introduced into the
treatment unit as the inoculum, as follows:
LA
=
Log No
-
Log N2A ? 6
where: LA is the log kill of the test microorganisms
(CFU and PFU) after treatment in challenge
load Type A.
No is the number of viable test
microorganisms (CFU and PFU) introduced into
the treatment unit as the inoculum.
N2A is the number of viable test
microorganisms (CFU and PFU) remaining after
treatment in challenge load Type A.
d) Repeat steps (a) through (c) in this option for
challenge loads Types B and C identified in Table C of
this Appendix to determine the effectiveness of the
treatment unit (LB and LC, respectively).
This Option 3 is for a treatment unit that uses thermal treatment
and maintains the integrity of the container of indicator
microorganism spores (e.g., autoclaves and incinerators).
a) One microbiological indicator assay containing at least
one million (1,000,000) spores of one of the indicator
microorganisms listed in Table B of this Appendix must
be placed in a sealed container that remains intact
during treatment. The inside diameter of the container
must be no larger than required to contain the assay
vial(s). The vial must contain only the indicator
microorganism vial.
b) The container of indicator microorganisms must be
placed within a Type A challenge load as identified in
Table C of this Appendix.
01 L~3-03L~.7
—86—
c) Calculate the effectiveness of the treatment unit by
subtracting the log of viable cells after treatment
from the log of viable cells introduced into the
treatment unit as the inoculum, as follows:
LA
=
Log No
-
Log N2A ? 6
where: LA is the log kill of the viable indicator
microorganisms (CFU) after treatment in
challenge load Type A.
No is the number of viable indicator
microorganisms (CFU) introduced into the
treatment unit as the inoculuin.
N2A is the number of viable indicator
microorganisms (CFU) remaining after
treatment in challenge load Type A.
d) Repeat steps (a) through (c) in this option for
challenge loads Types B and C identified in Table C of
this Appendix to determine the effectiveness of the
treatment unit (LB and LC, respectively).
Section 1422.APPENDIX A: Initial Efficacy Test Procedures
Table A: Test Microorganisms
1. Staphylococcus aureus (ATCC 6538)
2. Pseudomonas aeruginosa (ATCC 15442)
3. Candida albicans (ATCC 18804)
4.
Trichophyton mentagrophytes
(ATCC 9533)
5. MS—2 Bacteriophage (ATCC 15597—Bi)
6. Mycobacterium smegmatis (ATCC 14468)
Section 1422.APPENDIX A: Initial Efficacy Test Procedures
Table B: Indicator Microorganisms
1. Bacillus subtilis (ATCC 19659)
2. Bacillus stearothermophilus (ATCC 7953)
3. Bacillus pumulus (ATCC 27142)
Section 1422.APPENDIX A: Initial Efficacy Test Procedures
Table C: Challenge Loads
U! 4U’L~)4
—87—
This table identifies the three types of challenge loads of
P1MW that must be used as part of the Initial Efficacy Test
and Periodic Verification Test(s).
COMPOSITION OF CHALLENGE LOADS
(w/w)
--
—
C
Moisture
?50
Organic
?70
Section 1422.APPENDIX B: Correlating Periodic Verification Test
Procedures
a) A certified microbiological indicator assay containing the
test microorganisms and indicator microorganism spores is
introduced into each challenge load as identified in Table C
of Appendix A.
b) The test microorganisms and indicator microorganism spores
must be placed in a sealed container that remains intact
during treatment.
c) The container must be placed in each challenge load to
simulate the worst case scenario (i.e., that part of the
load that is the most difficult to treat). For example, the
worst case scenario for an autoclave would be to place the
test microorganisms and indicator microorganism spores
container within a sharps container that must in turn be
deposited in a plastic biohazard bag that is then located
centrally within the treatment unit.
d) The effectiveness of the treatment unit is demonstrated by
calculating the log kill (L) of the test microorganisms in
accordance with Option 2 of Appendix A of this Part. The
equivalent log kill (T) of the indicator microorganism
spores is calculated by subtracting the log of viable cells
after treatment from the log of viable cells introduced into
the treatment unit as the inoculum as follows:
TA
=
Log No
-
Log N2A ? 3
where: TA is the equivalent log kill of the viable
indicator microorganisms (CFU) after treatment in
challenge load Type A.
H
I
4’)
“~
U.J
—88—
No is the number of viable indicator microorganism
spores (CFU) introduced into the treatment unit as
the inoculum (? 6)
N2A is the number of viable indicator
microorganism (CFU) remaining after treatment in
challenge load Type A.
e) Repeat steps (a) through (d) for challenge loads Types B and
C identified in Table C of Appendix A to determine the
correlation between the log kill of the test microorganisms
and the equivalent kill of the indicator microorganism
spores (LB and LC, respectively).
IT IS SO ORDERED.
I, Dorothy 14. Gunn, Clerk of the Illinois Pollution
Control Board, hereby ce tify that the ove pinion and order
was adopted on the
/
day of ___________________________
1993, by a vote of 7—~O
.
~
~‘
~
Dorothy N. G)ztj~t, Clerk’
Illinois Po1~XitionControl Board
01 L~.3-Q350